

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 March 2010 (25.03.2010)

PCT

(10) International Publication Number
WO 2010/033223 A1

- (51) **International Patent Classification:**
A61K 47/48 (2006.01) *C07K 7/06* (2006.01)
- (21) **International Application Number:**
PCT/US2009/005212
- (22) **International Filing Date:**
17 September 2009 (17.09.2009)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/192,672 19 September 2008 (19.09.2008) US
61/153,948 19 February 2009 (19.02.2009) US
- (71) **Applicant (for all designated States except US):** **NEKTAR THERAPEUTICS** [US/US]; 201 Industrial Road, San Carlos, California 94070 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **FRY, Dennis** [US/US]; 126 Fred Atkinson Road, Huntsville, Alabama 35806 (US). **BREW, Christine Taylor** [US/US]; 836 Corona Drive, Pacifica, California 94044 (US). **ROCZ- NIAK, Steven O.** [US/US]; 678 Emerald Hill Road, Redwood City, California 94061 (US). **LIU, Xiaofeng** [CN/US]; 510 Seaside Court, Union City, California 94587 (US).
- (74) **Agents:** **DESAI, Naishadh** et al.; Nektar Therapeutics, 201 Industrial Road, San Carlos, California 94070 (US).

- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2010/033223 A1

(54) **Title:** POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES

(57) **Abstract:** The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.

POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Serial No. 61/153,948, filed 19 February 2009, and U.S. Provisional Patent Application Serial No. 61/192,672, filed 19 September 2008, the disclosures of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] Among other things, the present invention relates to conjugates comprising an OGF peptide moiety covalently attached to one or more water-soluble polymers.

BACKGROUND OF THE INVENTION

[0003] The opioid growth factor (OGF), chemically termed [Met⁵]-enkephalin, is an endogenous opioid peptide that is an important regulator of the progression of human head and neck squamous cell carcinoma (HNSCC). OGF is a constitutively expressed native opioid that is autocrine produced and secreted and interacts with the OGF receptor (OGFr) to inhibit the growth of HNSCC cells *in vitro* and in tumor xenografts. The action of OGF is tonic, stereospecific, reversible, noncytotoxic, and nonapoptotic-inducing, not associated with differentiative, migratory, invasive, or adhesive processes, independent of serum, anchorage-independent, and occurs at physiologically relevant concentrations in a wide variety of HNSCC cancers, including poorly and well-differentiated human cell lines. The only opioid peptide, natural or synthetic, that influences the growth of HNSCC is OGF. The action of this opioid in these neoplasias is targeted to DNA synthesis and is directed toward the G₀-G₁ interface of the cell cycle. Exogenous administration of OGF has a profound antitumor action on xenografts of HNSCC that includes delaying tumor appearance and reducing tumor size. The combination of biotherapy with OGF and chemotherapy with paclitaxel has proved to enhance antitumor effectiveness beyond either agent alone (See Cheng F. et al. (2007) *Cancer Research* 67, 10511-10518).

[0004] In pain modulation, the μ and δ (mu and delta, respectively) opioid receptors serve as classic binding sites for enkephalins. [Met⁵]-enkephalin binds to μ and δ receptors with high affinity and is reported to be 9.5 nM for μ and 0.9 nM for δ receptors in guinea-pig brain membranes (Leslie, 1987).

[0005] OGF has also been in clinical trials for pancreatic cancer and inhibits growth of pancreatic adenocarcinoma cell lines.

[0006] Normally, peptides, like OGF, suffer from a short in vivo half life, sometimes mere minutes, making them generally impractical, in their native form, for administration. Thus there exists a need in the art for modified OGF peptides having an enhanced half-life and/or reduced clearance as well as additional advantages as compared to the OGF peptides in their unmodified form.

SUMMARY OF THE INVENTION

[0007] Accordingly, the present invention provides conjugates comprising an OGF peptide moiety covalently attached to one or more water-soluble polymers. The water-soluble polymer may be stably bound to the OGF peptide moiety, or it may be releasably attached to the OGF peptide moiety.

[0008] The invention further provides methods of synthesizing such OGF peptide polymer conjugates and compositions comprising such conjugates. The invention further provides methods of treating, preventing, or ameliorating a disease, disorder or condition in a mammal comprising administering a therapeutically effective amount of an OGF peptide polymer conjugate of the invention.

[0009] Additional embodiments of the present conjugates, compositions, methods, and the like will be apparent from the following description, examples, and claims. As can be appreciated from the foregoing and following description, each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present disclosure provided that the features included in such a combination are not mutually inconsistent. In addition, any feature or combination of features may be specifically excluded from any embodiment of the present invention. Additional aspects and advantages of the present invention are set forth in the following description and claims, particularly when considered in conjunction with the accompanying examples and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. OGF2.1. Typical CG71S reversed phase purification profile of mono-[mPEG2-CAC-FMOC-40K]-[OGF].

Fig. OGF2.2. Purity analysis of [mono]-[CAC-PEG2-FOMC-40K]-[OGF] by reversed phase HPLC.

Fig. OGF2.3. MALDI-TOF spectrum of purified mono-[mPEG2-FMOC-CAC-40K]-[OGF].

Fig. OGF3.1. Typical CG71S reverse phase purification profile of mono-[mPEG2-C2-FMOC-40K]-[OGF].

Fig. OGF3.2. Purity analysis of mono-[mPEG2-FMOC-C2-40K]-[OGF] by reversed phase HPLC.

Fig. OGF3.3. MALDI-TOF spectrum of purified mono-[mPEG2-FMOC-C2-40K]-[OGF].

Fig. OGF4.1. Typical CG71S reversed phase purification profile of mono-[mPEG-Butyraldehyde-30K]-[OGF].

Fig. OGF4.2. Purity analysis of mono-[mPEG-Butyraldehyde-30K]-[OGF] by reversed phase HPLC.

Fig. OGF5.1. Typical CG71S reversed phase purification profile of mono-[mPEG-epoxide-5K]-[OGF].

Fig. OGF5.2. Purity analysis of mono-[mPEG-epoxide-5K]-[OGF] by reversed phase HPLC.

Fig. OGF6.1. Typical CG71S reversed phase purification profile of mono-[mPEG-Butyraldehyde-10K]-[OGF].

Fig. OGF6.2. Purity analysis of mono-[mPEG-Butyraldehyde-10K]-[OGF] by reversed phase HPLC.

Figure OGF7.1. Competition binding assay of OGF at human (A) μ opioid and (B) δ opioid receptors: effects of incubation treatment conditions.

Figure OGF7.2. Competition binding assay of OGF and PEG-OGF conjugates (released and unreleased) at human (A) μ opioid and (B) δ opioid receptors.

Figure OGF7.3. Competition binding assay of OGF and free PEGs at human (A) μ opioid and (B) δ opioid receptors.

DETAILED DESCRIPTION

[0010] As used in this specification and the intended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a polymer" includes a single polymer as well as two or more of the same or different polymers; reference to "an optional excipient" or to "a pharmaceutically acceptable excipient" refers to a single optional excipient as well as two or more of the same or different optional excipients, and the like.

[0011] In describing and claiming one or more embodiments of the present invention, the following terminology will be used in accordance with the definitions described below.

[0012] As used herein, the terms "OGF peptide" and "OGF peptides" mean one or more peptides having demonstrated or potential use in treating, preventing, or ameliorating one or more diseases, disorders, or conditions in a subject in need thereof, as well as related peptides. These terms may be used to refer to OGF peptides prior to conjugation to a water-soluble polymer as well as following the conjugation. OGF peptides include, but are not limited to, those having the amino acid sequence: Tyr-Gly-Gly-Phe-Met.

Table 1

SEQ ID NO.	Sequence
1	Tyr-Gly-Gly-Phe-Met

[0013] OGF peptides include peptides found to have use in treating, preventing, or ameliorating one or more diseases, disorders, or conditions after the time of filing of this application. Related peptides include fragments of OGF peptides, OGF peptide variants, and OGF peptide derivatives that retain some or all of the OGF-like activities of the OGF peptide. As will be known to one of skill in the art, as a general principle, modifications may be made to peptides that do not alter, or only partially abrogate, the properties and activities of those peptides. In some instances, modifications may be made that result in an increase in OGF activities. Thus, in the spirit of the invention, the terms "OGF peptide" and "OGF peptides" are meant to encompass modifications to the OGF peptides defined and/or disclosed herein that do not alter, only partially abrogate, or increase the OGF activities of the parent peptide.

[0014] The term "OGF activity" as used herein refers to a demonstrated or potential biological activity whose effect is consistent with a desirable disease outcome in humans, or to desired effects in non-human mammals or in other species or organisms. A given OGF peptide may have one or more OGF activities, however the term "OGF activities" as used herein may refer to a single OGF activity or multiple OGF activities. "OGF activity" includes the ability to induce a response *in vitro*, and may be measured *in vivo* or *in vitro*. For example, a desirable effect may be assayed in cell culture, or by clinical evaluation, EC₅₀ assays, IC₅₀ assays, or dose response curves. *In vitro* or cell culture assays, for example, are commonly available and known to one of skill in the art for many OGF peptides as defined and/or disclosed herein. OGF activity includes treatment, which may be prophylactic or ameliorative, or prevention of a disease, disorder, or condition. Treatment of a disease, disorder or condition can include improvement of a disease, disorder or condition by any amount, including elimination of a disease, disorder or condition.

[0015] As used herein, the terms "peptide," "polypeptide," and "protein," refer to polymers comprised of amino acid monomers linked by amide bonds. Peptides may include the standard 20 α -amino acids that are used in protein synthesis by cells (*i.e.* natural amino acids), as well as non-natural amino acids (non-natural amino acids may be found in nature, but not used in protein synthesis by cells, *e.g.*, ornithine, citrulline, and sarcosine, or may be chemically synthesized), amino acid analogs, and peptidomimetics. Spatola, (1983) in *Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins*, Weinstein, ed., Marcel Dekker, New York, p. 267. The amino acids may be D- or L-optical isomers. Peptides may be formed by a condensation or coupling reaction between the α -carbon carboxyl group of one amino acid and the amino group of another amino acid. The terminal amino acid at one end of the chain (amino terminal) therefore has a free amino group, while the terminal amino acid at the other end of the chain (carboxy terminal) has a free carboxyl group. Alternatively, the peptides may be non-linear, branched peptides or cyclic peptides. Moreover, the peptides may optionally be modified or protected with a variety of functional groups or protecting groups, including on the amino and/or carboxy terminus.

[0016] Amino acid residues in peptides are abbreviated as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is Ile or I; Methionine is Met or M; Valine is Val or V; Serine is Ser or S; Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y; Histidine is His or H; Glutamine is Gln or Q; Asparagine is Asn or N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid is Glu or E; Cysteine is Cys or C; Tryptophan is Trp or W; Arginine is Arg or R; and Glycine is Gly or G.

[0017] The terms "OGF peptide fragment" or "fragments of OGF peptides" refer to a polypeptide that comprises a truncation at the amino-terminus and/or a truncation at the carboxyl-terminus of an OGF peptide as defined herein. The terms "OGF peptide fragment" or "fragments of OGF peptides" also encompasses amino-terminal and/or carboxyl-terminal truncations of OGF peptide variants and OGF peptide derivatives. OGF peptide fragments may be produced by synthetic techniques known in the art or may arise from *in vivo* protease activity on longer peptide sequences. It will be understood that OGF peptide fragments retain some or all of the OGF activities of the OGF peptides.

[0018] As used herein, the terms "OGF peptide variants" or "variants of OGF peptides" refer to OGF peptides having one or more amino acid substitutions, including conservative substitutions and non-conservative substitutions, amino acid deletions (either internal deletions and/or C- and/or N- terminal truncations), amino acid additions (either internal additions and/or C- and/or N- terminal additions, *e.g.*, fusion peptides), or any

combination thereof. Variants may be naturally occurring (*e.g.* homologs or orthologs), or non-natural in origin. The term "OGF peptide variants" may also be used to refer to OGF peptides incorporating one or more non-natural amino acids, amino acid analogs, and peptidomimetics. It will be understood that, in accordance with the invention, OGF peptide fragments retain some or all of the OGF activities of the OGF peptides.

[0019] The terms "OGF peptide derivatives" or "derivatives of OGF peptides" as used herein refer to OGF peptides, OGF peptide fragments, and OGF peptide variants that have been chemically altered other than through covalent attachment of a water-soluble polymer. It will be understood that, in accordance with the invention, OGF peptide derivatives retain some or all of the OGF activities of the OGF peptides.

[0020] As used herein, the terms "amino terminus protecting group" or "N-terminal protecting group," "carboxy terminus protecting group" or "C-terminal protecting group," or "side chain protecting group" refer to any chemical moiety capable of addition to and optionally removal from a functional group on a peptide (*e.g.*, the *N*-terminus, the *C*-terminus, or a functional group associated with the side chain of an amino acid located within the peptide) to allow for chemical manipulation of the peptide.

[0021] "PEG," "polyethylene glycol" and "poly(ethylene glycol)" as used herein, are interchangeable and encompass any nonpeptidic water-soluble poly(ethylene oxide). Typically, PEGs for use in accordance with the invention comprise the following structure $-(\text{OCH}_2\text{CH}_2)_n-$ where (n) is 2 to 4000. As used herein, PEG also includes $-\text{CH}_2\text{CH}_2-\text{O}(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-$ and $-(\text{OCH}_2\text{CH}_2)_n\text{O}-$, depending upon whether or not the terminal oxygens have been displaced. Throughout the specification and claims, it should be remembered that the term "PEG" includes structures having various terminal or "end capping" groups and so forth. The term "PEG" also means a polymer that contains a majority, that is to say, greater than 50%, of $-\text{OCH}_2\text{CH}_2-$ repeating subunits. With respect to specific forms, the PEG can take any number of a variety of molecular weights, as well as structures or geometries such as "branched," "linear," "forked," "multifunctional," and the like, to be described in greater detail below.

[0022] The terms "end-capped" and "terminally capped" are interchangeably used herein to refer to a terminal or endpoint of a polymer having an end-capping moiety. Typically, although not necessarily, the end-capping moiety comprises a hydroxy or C_{1-20} alkoxy group, more preferably a C_{1-10} alkoxy group, and still more preferably a C_{1-5} alkoxy group. Thus, examples of end-capping moieties include alkoxy (*e.g.*, methoxy, ethoxy and

benzyloxy), as well as aryl, heteroaryl, cyclo, heterocyclo, and the like. It must be remembered that the end-capping moiety may include one or more atoms of the terminal monomer in the polymer [e.g., the end-capping moiety "methoxy" in $\text{CH}_3\text{O}(\text{CH}_2\text{CH}_2\text{O})_n$ - and $\text{CH}_3(\text{OCH}_2\text{CH}_2)_n$]. In addition, saturated, unsaturated, substituted and unsubstituted forms of each of the foregoing are envisioned. Moreover, the end-capping group can also be a silane. The end-capping group can also advantageously comprise a detectable label. When the polymer has an end-capping group comprising a detectable label, the amount or location of the polymer and/or the moiety (e.g., active agent) to which the polymer is coupled can be determined by using a suitable detector. Such labels include, without limitation, fluorescers, chemiluminescers, moieties used in enzyme labeling, colorimetric (e.g., dyes), metal ions, radioactive moieties, gold particles, quantum dots, and the like. Suitable detectors include photometers, films, spectrometers, and the like. The end-capping group can also advantageously comprise a phospholipid. When the polymer has an end-capping group comprising a phospholipid, unique properties are imparted to the polymer and the resulting conjugate. Exemplary phospholipids include, without limitation, those selected from the class of phospholipids called phosphatidylcholines. Specific phospholipids include, without limitation, those selected from the group consisting of dilauroylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteoylphosphatidylcholine, behenoylphosphatidylcholine, arachidoylphosphatidylcholine, and lecithin.

[0023] The term "targeting moiety" is used herein to refer to a molecular structure that helps the conjugates of the invention to localize to a targeting area, e.g., help enter a cell, or bind a receptor. Preferably, the targeting moiety comprises of vitamin, antibody, antigen, receptor, DNA, RNA, sialyl Lewis X antigen, hyaluronic acid, sugars, cell specific lectins, steroid or steroid derivative, RGD peptide, ligand for a cell surface receptor, serum component, or combinatorial molecule directed against various intra- or extracellular receptors. The targeting moiety may also comprise a lipid or a phospholipid. Exemplary phospholipids include, without limitation, phosphatidylcholines, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and phosphatidylethanolamine. These lipids may be in the form of micelles or liposomes and the like. The targeting moiety may further comprise a detectable label or alternately a detectable label may serve as a targeting moiety. When the conjugate has a targeting group comprising a detectable label, the amount and/or distribution/location of the polymer and/or the moiety (e.g., active agent) to which the polymer is coupled can be determined by using a suitable detector. Such labels include,

without limitation, fluorescers, chemiluminescers, moieties used in enzyme labeling, colorimetric (e.g., dyes), metal ions, radioactive moieties, gold particles, quantum dots, and the like.

[0024] "Non-naturally occurring" with respect to a polymer as described herein, means a polymer that in its entirety is not found in nature. A non-naturally occurring polymer of the invention may, however, contain one or more monomers or segments of monomers that are naturally occurring, so long as the overall polymer structure is not found in nature.

[0025] The term "water soluble" as in a "water-soluble polymer" is any polymer that is soluble in water at room temperature. Typically, a water-soluble polymer will transmit at least about 75%, more preferably at least about 95%, of light transmitted by the same solution after filtering. On a weight basis, a water-soluble polymer will preferably be at least about 35% (by weight) soluble in water, more preferably at least about 50% (by weight) soluble in water, still more preferably about 70% (by weight) soluble in water, and still more preferably about 85% (by weight) soluble in water. It is most preferred, however, that the water-soluble polymer is about 95% (by weight) soluble in water or completely soluble in water.

[0026] "Hydrophilic," e.g., in reference to a "hydrophilic polymer," refers to a polymer that is characterized by its solubility in and compatability with water. In non-cross linked form, a hydrophilic polymer is able to dissolve in, or be dispersed in water. Typically, a hydrophilic polymer possesses a polymer backbone composed of carbon and hydrogen, and generally possesses a high percentage of oxygen in either the main polymer backbone or in pendent groups substituted along the polymer backbone, thereby leading to its "water-loving" nature. The water-soluble polymers of the present invention are typically hydrophilic, e.g., non-naturally occurring hydrophilic.

[0027] Molecular weight in the context of a water-soluble polymer, such as PEG, can be expressed as either a number average molecular weight or a weight average molecular weight. Unless otherwise indicated, all references to molecular weight herein refer to the weight average molecular weight. Both molecular weight determinations, number average and weight average, can be measured using gel permeation chromatography or other liquid chromatography techniques. Other methods for measuring molecular weight values can also be used, such as the use of end-group analysis or the measurement of colligative properties (e.g., freezing-point depression, boiling-point elevation, and osmotic pressure) to determine number average molecular weight, or the use of light scattering techniques,

ultracentrifugation or viscometry to determine weight average molecular weight. The polymers of the invention are typically polydisperse (i.e., number average molecular weight and weight average molecular weight of the polymers are not equal), possessing low polydispersity values of preferably less than about 1.2, more preferably less than about 1.15, still more preferably less than about 1.10, yet still more preferably less than about 1.05, and most preferably less than about 1.03.

[0028] The term "active" or "activated" when used in conjunction with a particular functional group refers to a reactive functional group that reacts readily with an electrophile or a nucleophile on another molecule. This is in contrast to those groups that require strong catalysts or highly impractical reaction conditions in order to react (i.e., a "non-reactive" or "inert" group).

[0029] As used herein, the term "functional group" or any synonym thereof is meant to encompass protected forms thereof as well as unprotected forms.

[0030] The terms "spacer moiety," "linkage" and "linker" are used herein to refer to an atom or a collection of atoms optionally used to link interconnecting moieties such as a terminus of a polymer segment and an OGF peptide or an electrophile or nucleophile of an OGF peptide. The spacer moiety may be hydrolytically stable or may include a physiologically hydrolyzable or enzymatically degradable linkage. Unless the context clearly dictates otherwise, a spacer moiety optionally exists between any two elements of a compound (e.g., the provided conjugates comprising a residue of an OGF peptide and a water-soluble polymer that can be attached directly or indirectly through a spacer moiety).

[0031] A "monomer" or "mono-conjugate," in reference to a polymer conjugate of an OGF peptide, refers to an OGF peptide having only one water-soluble polymer molecule covalently attached thereto, whereas an OGF peptide "dimer" or "di-conjugate" is a polymer conjugate of an OGF peptide having two water-soluble polymer molecules covalently attached thereto, and so forth.

[0032] "Alkyl" refers to a hydrocarbon, typically ranging from about 1 to 15 atoms in length. Such hydrocarbons are preferably but not necessarily saturated and may be branched or straight chain, although typically straight chain is preferred. Exemplary alkyl groups include methyl, ethyl, propyl, butyl, pentyl, 2-methylbutyl, 2-ethylpropyl, 3-methylpentyl, and the like. As used herein, "alkyl" includes cycloalkyl as well as cycloalkylene-containing alkyl.

[0033] "Lower alkyl" refers to an alkyl group containing from 1 to 6 carbon atoms, and may be straight chain or branched, as exemplified by methyl, ethyl, *n*-butyl, *i*-butyl, and *t*-butyl.

[0034] "Cycloalkyl" refers to a saturated or unsaturated cyclic hydrocarbon chain, including bridged, fused, or spiro cyclic compounds, preferably made up of 3 to about 12 carbon atoms, more preferably 3 to about 8 carbon atoms. "Cycloalkylene" refers to a cycloalkyl group that is inserted into an alkyl chain by bonding of the chain at any two carbons in the cyclic ring system.

[0035] "Alkoxy" refers to an -O-R group, wherein R is alkyl or substituted alkyl, preferably C₁₋₆ alkyl (*e.g.*, methoxy, ethoxy, propyloxy, and so forth).

[0036] The term "substituted" as in, for example, "substituted alkyl," refers to a moiety (*e.g.*, an alkyl group) substituted with one or more noninterfering substituents, such as, but not limited to: alkyl; C₃₋₈ cycloalkyl, *e.g.*, cyclopropyl, cyclobutyl, and the like; halo, *e.g.*, fluoro, chloro, bromo, and iodo; cyano; alkoxy, lower phenyl; substituted phenyl; and the like. "Substituted aryl" is aryl having one or more noninterfering groups as a substituent. For substitutions on a phenyl ring, the substituents may be in any orientation (*i.e.*, ortho, meta, or para).

[0037] "Noninterfering substituents" are those groups that, when present in a molecule, are typically nonreactive with other functional groups contained within the molecule.

[0038] "Aryl" means one or more aromatic rings, each of 5 or 6 core carbon atoms. Aryl includes multiple aryl rings that may be fused, as in naphthyl or unfused, as in biphenyl. Aryl rings may also be fused or unfused with one or more cyclic hydrocarbon, heteroaryl, or heterocyclic rings. As used herein, "aryl" includes heteroaryl.

[0039] "Heteroaryl" is an aryl group containing from one to four heteroatoms, preferably sulfur, oxygen, or nitrogen, or a combination thereof. Heteroaryl rings may also be fused with one or more cyclic hydrocarbon, heterocyclic, aryl, or heteroaryl rings.

[0040] "Heterocycle" or "heterocyclic" means one or more rings of 5-12 atoms, preferably 5-7 atoms, with or without unsaturation or aromatic character and having at least one ring atom that is not a carbon. Preferred heteroatoms include sulfur, oxygen, and nitrogen.

[0041] "Substituted heteroaryl" is heteroaryl having one or more noninterfering groups as substituents.

[0042] "Substituted heterocycle" is a heterocycle having one or more side chains formed from noninterfering substituents.

[0043] An "organic radical" as used herein shall include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, and substituted aryl.

[0044] "Electrophile" and "electrophilic group" refer to an ion or atom or collection of atoms, that may be ionic, having an electrophilic center, *i.e.*, a center that is electron seeking, capable of reacting with a nucleophile.

[0045] "Nucleophile" and "nucleophilic group" refers to an ion or atom or collection of atoms that may be ionic having a nucleophilic center, *i.e.*, a center that is seeking an electrophilic center or with an electrophile.

[0046] A "physiologically cleavable" or "hydrolyzable" or "degradable" bond is a bond that reacts with water (*i.e.*, is hydrolyzed) under physiological conditions. The tendency of a bond to hydrolyze in water will depend not only on the general type of linkage connecting two central atoms but also on the substituents attached to these central atoms. Appropriate hydrolytically unstable or weak linkages include but are not limited to carboxylate ester, phosphate ester, anhydrides, acetals, ketals, acyloxyalkyl ether, imines, orthoesters, peptides and oligonucleotides.

[0047] "Releasably attached," *e.g.*, in reference to an OGF peptide releasably attached to a water-soluble polymer, refers to an OGF peptide that is covalently attached via a linker that includes a degradable linkage as disclosed herein, wherein upon degradation (*e.g.*, hydrolysis), the OGF peptide is released. The OGF peptide thus released will typically correspond to the unmodified parent or native OGF peptide, or may be slightly altered, *e.g.*, possessing a short organic tag. Preferably, the unmodified parent OGF peptide is released.

[0048] An "enzymatically degradable linkage" means a linkage that is subject to degradation by one or more enzymes.

[0049] A "hydrolytically stable" linkage or bond refers to a chemical bond, typically a covalent bond, that is substantially stable in water, that is to say, does not undergo hydrolysis under physiological conditions to any appreciable extent over an extended period of time. Examples of hydrolytically stable linkages include, but are not limited to, the following: carbon-carbon bonds (*e.g.*, in aliphatic chains), ethers, amides, urethanes, and the like. Generally, a hydrolytically stable linkage is one that exhibits a rate of hydrolysis of less than about 1-2% per day under physiological conditions. Hydrolysis rates of representative

chemical bonds can be found in most standard chemistry textbooks. It must be pointed out that some linkages can be hydrolytically stable or hydrolyzable, depending upon (for example) adjacent and neighboring atoms and ambient conditions. One of ordinary skill in the art can determine whether a given linkage or bond is hydrolytically stable or hydrolyzable in a given context by, for example, placing a linkage-containing molecule of interest under conditions of interest and testing for evidence of hydrolysis (*e.g.*, the presence and amount of two molecules resulting from the cleavage of a single molecule). Other approaches known to those of ordinary skill in the art for determining whether a given linkage or bond is hydrolytically stable or hydrolyzable can also be used.

[0050] The terms "pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to an excipient that may optionally be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.

[0051] "Pharmacologically effective amount," "physiologically effective amount," and "therapeutically effective amount" are used interchangeably herein to mean the amount of a polymer-(OGF peptide) conjugate that is needed to provide a desired level of the conjugate (or corresponding unconjugated OGF peptide) in the bloodstream or in the target tissue. The precise amount will depend upon numerous factors, *e.g.*, the particular OGF peptide, the components and physical characteristics of the OGF composition, intended patient population, individual patient considerations, and the like, and can readily be determined by one skilled in the art, based upon the information provided herein.

[0052] "Multi-functional" means a polymer having three or more functional groups contained therein, where the functional groups may be the same or different. Multi-functional polymeric reagents of the invention will typically contain from about 3-100 functional groups, or from 3-50 functional groups, or from 3-25 functional groups, or from 3-15 functional groups, or from 3 to 10 functional groups, or will contain 3, 4, 5, 6, 7, 8, 9 or 10 functional groups within the polymer backbone. A "difunctional" polymer means a polymer having two functional groups contained therein, either the same (*i.e.*, homodifunctional) or different (*i.e.*, heterodifunctional).


[0053] The terms "subject," "individual," or "patient" are used interchangeably herein and refer to a vertebrate, preferably a mammal. Mammals include, but are not limited to, murines, rodents, simians, humans, farm animals, sport animals, and pets.

[0054] "Optional" or "optionally" means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.

[0055] "Substantially" (unless specifically defined for a particular context elsewhere or the context clearly dictates otherwise) means nearly totally or completely, for instance, satisfying one or more of the following: greater than 50%, 51% or greater, 75% or greater, 80% or greater, 90% or greater, and 95% or greater of the condition.

[0056] Unless the context clearly dictates otherwise, when the term "about" precedes a numerical value, the numerical value is understood to mean the stated numerical value and also $\pm 10\%$ of the stated numerical value.

[0057] Turning now to one or more aspects of the invention, conjugates are provided, the conjugates comprising an OGF peptide covalently attached (either directly or through a spacer moiety or linker) to a water-soluble polymer. The conjugates generally have the following formula:



wherein OGF is an OGF peptide as defined herein, X is a covalent bond or is a spacer moiety or linker, POLY is a water soluble polymer, and k is an integer ranging from 1-10, preferably 1-5, and more preferably 1-3.

OGF Peptides

[0058] As previously stated, the conjugates of the invention comprise an OGF peptide as disclosed and/or defined herein. OGF peptides include those currently known to have demonstrated or potential use in treating, preventing, or ameliorating one or more diseases, disorders, or conditions in a subject in need thereof as well as those discovered after the filing of this application. OGF peptides also include related peptides.

[0059] The OGF peptides of the invention may comprise any of the 20 natural amino acids, and/or non-natural amino acids, amino acid analogs, and peptidomimetics, in any combination. The peptides may be composed of D- amino acids or L-amino acids, or a combination of both in any proportion. In addition to natural amino acids, the OGF peptides may contain, or may be modified to include, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or more non-natural amino acids. Exemplary non-natural amino acids and amino acid analogs that can be use with the invention include, but are not limited to, 2-aminobutyric acid, 2-aminoisobutyric acid, 3-(1-naphthyl)alanine, 3-(2-naphthyl)alanine, 3-methylhistidine, 3-

pyridylalanine, 4-chlorophenylalanine, 4-fluorophenylalanine, 4-hydroxyproline, 5-hydroxylysine, alloisoleucine, citrulline, dehydroalanine, homoarginine, homocysteine, homoserine, hydroxyproline, N-acetylserine, N-formylmethionine, N-methylglycine, N-methylisoleucine, norleucine, N- α -methylarginine, O-phosphoserine, ornithine, phenylglycine, pipercolinic acid, piperazic acid, pyroglutamine, sarcosine, valanine, β -alanine, and β -cyclohexylalanine.

[0060] The OGF peptides may be, or may be modified to be, linear, branched, or cyclic, with or without branching.

[0061] Additionally, the OGF peptides may optionally be modified or protected with a variety of functional groups or protecting groups, including amino terminus protecting groups and/or carboxy terminus protecting groups. Protecting groups, and the manner in which they are introduced and removed are described, for example, in "Protective Groups in Organic Chemistry," Plenum Press, London, N.Y. 1973; and Greene *et al.*, "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS" 3rd Edition, John Wiley and Sons, Inc., New York, 1999. Numerous protecting groups are known in the art. An illustrative, non-limiting list of protecting groups includes methyl, formyl, ethyl, acetyl, t-butyl, anisyl, benzyl, trifluoroacetyl, N-hydroxysuccinimide, t-butoxycarbonyl, benzoyl, 4-methylbenzyl, thioanisyl, thiocresyl, benzyloxymethyl, 4-nitrophenyl, benzyloxycarbonyl, 2-nitrobenzoyl, 2-nitrophenylsulphenyl, 4-toluenesulphonyl, pentafluorophenyl, diphenylmethyl, 2-chlorobenzyloxycarbonyl, 2,4,5-trichlorophenyl, 2-bromobenzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, triphenylmethyl, and 2,2,5,7,8-pentamethyl-chroman-6-sulphonyl. For discussions of various different types of amino- and carboxy-protecting groups, see, for example, U.S. Pat. No. 5,221,736 (issued Jun. 22, 1993); U.S. Pat. No. 5,256,549 (issued Oct. 26, 1993); U.S. Pat. No. 5,049,656 (issued Sep. 17, 1991); and U.S. Pat. No. 5,521,184 (issued May 28, 1996).

[0062] The OGF peptides contain, or may be modified to contain, functional groups to which a water-soluble polymer may be attached, either directly or through a spacer moiety or linker. Functional groups include, but are not limited to, the N-terminus of the OGF peptide, the C-terminus of the OGF peptide, and any functional groups on the side chain of an amino acid, *e.g.* lysine, cysteine, histidine, aspartic acid, glutamic acid, tyrosine, arginine, serine, methionine, and threonine, present in the OGF peptide.

[0063] The OGF peptides can be prepared by any means known in the art, including non-recombinant and recombinant methods, or they may, in some instances, be commercially available. Chemical or non-recombinant methods include, but are not limited to, solid phase

peptide synthesis (SPPS), solution phase peptide synthesis, native chemical ligation, intein-mediated protein ligation, and chemical ligation, or a combination thereof. In a preferred embodiment, the OGF peptides are synthesized using standard SPPS, either manually or by using commercially available automated SPPS synthesizers.

[0064] SPPS has been known in the art since the early 1960's (Merrifield, R. B., *J. Am. Chem. Soc.*, 85:2149-2154 (1963)), and is widely employed. (*See also*, Bodanszky, Principles of Peptide Synthesis, Springer-Verlag, Heidelberg (1984)). There are several known variations on the general approach. (*See*, for example, "Peptide Synthesis, Structures, and Applications" © 1995 by Academic Press, Chapter 3 and White (2003) *Fmoc Solid Phase Peptide Synthesis, A practical Approach*, Oxford University Press, Oxford). Very briefly, in solid phase peptide synthesis, the desired C-terminal amino acid residue is coupled to a solid support. The subsequent amino acid to be added to the peptide chain is protected on its amino terminus with Boc, Fmoc, or other suitable protecting group, and its carboxy terminus is activated with a standard coupling reagent. The free amino terminus of the support-bound amino acid is allowed to react with the carboxy-terminus of the subsequent amino acid, coupling the two amino acids. The amino terminus of the growing peptide chain is deprotected, and the process is repeated until the desired polypeptide is completed. Side chain protecting groups may be utilized as needed.

[0065] Alternatively, the OGF peptides may be prepared recombinantly. Exemplary recombinant methods used to prepare OGF peptides include the following, among others, as will be apparent to one skilled in the art. Typically, an OGF peptide as defined and/or described herein is prepared by constructing the nucleic acid encoding the desired peptide or fragment, cloning the nucleic acid into an expression vector, transforming a host cell (*e.g.*, plant, bacteria such as *Escherichia coli*, yeast such as *Saccharomyces cerevisiae*, or mammalian cell such as Chinese hamster ovary cell or baby hamster kidney cell), and expressing the nucleic acid to produce the desired peptide or fragment. The expression can occur via exogenous expression or via endogenous expression (when the host cell naturally contains the desired genetic coding). Methods for producing and expressing recombinant polypeptides *in vitro* and in prokaryotic and eukaryotic host cells are known to those of ordinary skill in the art. *See*, for example, U.S. Patent No. 4,868,122, and Sambrook et al., *Molecular Cloning--A Laboratory Manual* (Third Edition), Cold Spring Harbor Laboratory Press (2001).

[0066] To facilitate identification and purification of the recombinant peptide, nucleic acid sequences that encode an epitope tag or other affinity binding sequence can be inserted or added in-frame with the coding sequence, thereby producing a fusion peptide comprised of the desired OGF peptide and a peptide suited for binding. Fusion peptides can be identified and purified by first running a mixture containing the fusion peptide through an affinity column bearing binding moieties (*e.g.*, antibodies) directed against the epitope tag or other binding sequence in the fusion peptide, thereby binding the fusion peptide within the column. Thereafter, the fusion peptide can be recovered by washing the column with the appropriate solution (*e.g.*, acid) to release the bound fusion peptide. Optionally, the tag may subsequently be removed by techniques known in the art. The recombinant peptide can also be identified and purified by lysing the host cells, separating the peptide, *e.g.*, by size exclusion chromatography, and collecting the peptide. These and other methods for identifying and purifying recombinant peptides are known to those of ordinary skill in the art.

Related Peptides

[0067] It will be appreciated and understood by one of skill in the art that certain modifications can be made to the OGF peptides defined and/or disclosed herein that do not alter, or only partially abrogate, the properties and activities of these OGF peptides. In some instances, modifications may be made that result in an increase in OGF activities. Additionally, modifications may be made that increase certain biological and chemical properties of the OGF peptides in a beneficial way, *e.g.* increased *in vivo* half life, increased stability, decreased susceptibility to proteolytic cleavage, etc. Thus, in the spirit and scope of the invention, the term "OGF peptide" is used herein in a manner to include not only the OGF peptides defined and/or disclosed herein, but also related peptides, *i.e.* peptides that contain one or more modifications relative to the OGF peptides defined and/or disclosed herein, wherein the modification(s) do not alter, only partially abrogate, or increase the OGF activities as compared to the parent peptide.

[0068] Related peptides include, but are not limited to, fragments of OGF peptides, OGF peptide variants, and OGF peptide derivatives. Related peptides also include any and all combinations of these modifications. In a non-limiting example, a related peptide may be a fragment of an OGF peptide as disclosed herein having one or more amino acid substitutions. Thus it will be understood that any reference to a particular type of related peptide is not limited to an OGF peptide having only that particular modification, but rather

encompasses an OGF peptide having that particular modification and optionally any other modification.

[0069] Related peptides may be prepared by action on a parent peptide or a parent protein (*e.g.* proteolytic digestion to generate fragments) or through *de novo* preparation (*e.g.* solid phase synthesis of a peptide having a conservative amino acid substitution relative to the parent peptide). Related peptides may arise by natural processes (*e.g.* processing and other post-translational modifications) or may be made by chemical modification techniques. Such modifications are well-known to those of skill in the art.

[0070] A related peptide may have a single alteration or multiple alterations relative to the parent peptide. Where multiple alterations are present, the alterations may be of the same type or a given related peptide may contain different types of modifications. Furthermore, modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the *N*- or *C*- termini.

[0071] As previously noted, related peptides include fragments of the OGF peptides defined and/or disclosed herein, wherein the fragment retains some of or all of at least one OGF activity of the parent peptide. The fragment may also exhibit an increase in at least one OGF activity of the parent peptide. In certain embodiments of the invention, OGF peptides include related peptides having at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 contiguous amino acid residues, or more than 125 contiguous amino acid residues, of any of the OGF peptides disclosed, herein, including in Table 1. In other embodiments of the invention, OGF peptides include related peptides having 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid residues deleted from the *N*-terminus and/or having 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid residues deleted from the *C*-terminus of any of the OGF peptides disclosed herein, including in Table 1.

[0072] Related peptides also include variants of the OGF peptides defined and/or disclosed herein, wherein the variant retains some of or all of at least one OGF activity of the parent peptide. The variant may also exhibit an increase in at least one OGF activity of the parent peptide. In certain embodiments of the invention, OGF peptides include variants having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 conservative and/or non-conservative amino acid substitutions relative to the OGF peptides disclosed herein, including in Table 1. Desired amino acid substitutions, whether conservative or non-conservative, can be determined by those skilled in the art.

[0073] In certain embodiments of the invention, OGF peptides include variants having conservative amino substitutions; these substitutions will produce an OGF peptide having functional and chemical characteristics similar to those of the parent peptide. In other embodiments, OGF peptides include variants having non-conservative amino substitutions; these substitutions will produce an OGF peptide having functional and chemical characteristics that may differ substantially from those of the parent peptide. In certain embodiments of the invention, OGF peptide variants have both conservative and non-conservative amino acid substitutions. In other embodiments, each amino acid residue may be substituted with alanine.

[0074] Natural amino acids may be divided into classes based on common side chain properties: nonpolar (Gly, Ala, Val, Leu, Ile, Met); polar neutral (Cys, Ser, Thr, Pro, Asn, Gln); acidic (Asp, Glu); basic (His, Lys, Arg); and aromatic (Trp, Tyr, Phe). By way of example, non-conservative amino acid substitutions may involve the substitution of an amino acid of one class for that of another, and may be introduced in regions of the peptide not critical for OGF activity.

[0075] Preferably, amino acid substitutions are conservative. Conservative amino acid substitutions may involve the substitution of an amino acid of one class for that of the same class. Conservative amino acid substitutions may also encompass non-natural amino acid residues, including peptidomimetics and other atypical forms of amino acid moieties, and may be incorporated through chemical peptide synthesis,

[0076] Amino acid substitutions may be made with consideration to the hydrophobic index of amino acids. The importance of the hydrophobic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte *et al.*, 1982, *J. Mol. Biol.* 157:105-31). Each amino acid has been assigned a hydrophobic index on the basis of its hydrophobicity and charge characteristics. The hydrophobic indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

[0077] It is known that certain amino acids may be substituted for other amino acids having a similar hydrophobic index or score and still retain a similar biological activity. In making changes based upon the hydrophobic index, the substitution of amino acids whose hydrophobic indices are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

[0078] It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. The greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its biological properties. According to U.S. Patent No. 4,554,101, incorporated herein by reference, the following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4). In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

[0079] In certain embodiments of the invention, OGF peptides include variants having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid deletions relative to the OGF peptides disclosed herein, including in Table 1. The deleted amino acid(s) may be at the *N*- or *C*- terminus of the peptide, at both termini, at an internal location or locations within the peptide, or both internally and at one or both termini. Where the variant has more than one amino acid deletion, the deletions may be of contiguous amino acids or of amino acids at different locations within the primary amino acid sequence of the parent peptide.

[0080] In other embodiments of the invention, OGF peptides include variants having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid additions relative to the OGF peptides disclosed herein, including in Table 1. The added amino acid(s) may be at the *N*- or *C*- terminus of the peptide, at both termini, at an internal location or locations within the peptide, or both internally and at one or both termini. Where the variant has more than one amino acid addition, the amino acids may be added contiguously, or the amino acids may be added at different locations within the primary amino acid sequence of the parent peptide.

[0081] Addition variants also include fusion peptides. Fusions can be made either at the *N*-terminus or at the *C*-terminus of the OGF peptides disclosed herein, including in Table 1. In certain embodiments, the fusion peptides have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid additions relative to the OGF peptides disclosed herein, including in Table 1. Fusions may be attached directly to the OGF peptide with no connector molecule or may be through a connector molecule. As used in this context, a connector molecule may be an atom or a collection of atoms optionally used to link an OGF peptide to

another peptide. Alternatively, the connector may be an amino acid sequence designed for cleavage by a protease to allow for the separation of the fused peptides.

[0082] The OGF peptides of the invention may be fused to peptides designed to improve certain qualities of the OGF peptide, such as OGF activity, circulation time, or reduced aggregation. OGF peptides may be fused to an immunologically active domain, *e.g.* an antibody epitope, to facilitate purification of the peptide, or to increase the *in vivo* half life of the peptide. Additionally, OGF peptides may be fused to known functional domains, cellular localization sequences, or peptide permeant motifs known to improve membrane transfer properties.

[0083] In certain embodiments of the invention, OGF peptides also include variants incorporating one or more non-natural amino acids, amino acid analogs, and peptidomimetics. Thus the present invention encompasses compounds structurally similar to the OGF peptides defined and/or disclosed herein, which are formulated to mimic the key portions of the OGF peptides of the present invention. Such compounds may be used in the same manner as the OGF peptides of the invention. Certain mimetics that mimic elements of protein secondary and tertiary structure have been previously described. Johnson *et al.*, Biotechnology and Pharmacy, Pezzuto et al. (Eds.), Chapman and Hall, NY, 1993. The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions. A peptide mimetic is thus designed to permit molecular interactions similar to the parent peptide. Mimetics can be constructed to achieve a similar spatial orientation of the essential elements of the amino acid side chains. Methods for generating specific structures have been disclosed in the art. For example, U.S. Patent Nos. 5,446,128, 5,710,245, 5,840,833, 5,859,184, 5,440,013; 5,618,914, 5,670,155, 5,475,085, 5,929,237, 5,672,681 and 5,674,976, the contents of which are hereby incorporated by reference, all disclose peptidomimetics structures that may have improved properties over the parent peptide, for example they may be conformationally restricted, be more thermally stable, exhibit increased resistance to degradation, etc.

[0084] In another embodiment, related peptides comprise or consist of a peptide sequence that is at least 70% identical to any of the OGF peptides disclosed herein, including in Table 1. In additional embodiments, related peptides are at least 75% identical, at least 80% identical, at least 85% identical, 90% identical, at least 91% identical, at least 92% identical, 93% identical, at least 94% identical, at least 95% identical, 96% identical, at least

97% identical, at least 98% identical, or at least 99% identical to any of the OGF peptides disclosed herein, including in Table 1.

[0085] Sequence identity (also known as % homology) of related polypeptides can be readily calculated by known methods. Such methods include, but are not limited to those described in *Computational Molecular Biology* (A.M. Lesk, ed., Oxford University Press 1988); *Biocomputing: Informatics and Genome Projects* (D.W. Smith, ed., Academic Press 1993); *Computer Analysis of Sequence Data* (Part 1, A.M. Griffin and H.G. Griffin, eds., Humana Press 1994); G. von Heinle, *Sequence Analysis in Molecular Biology* (Academic Press 1987); *Sequence Analysis Primer* (M. Gribskov and J. Devereux, eds., M. Stockton Press 1991); and Carillo *et al.*, 1988, *SIAM J. Applied Math.*, 48:1073.

[0086] Preferred methods to determine sequence identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine sequence identity are described in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux *et al.*, 1984, *Nucleic Acids Res.* 12:387; Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, and FASTA (Altschul *et al.*, 1990, *J. Mol. Biol.* 215:403-10). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (Altschul *et al.*, *BLAST Manual* (NCB NLM NIH, Bethesda, MD); Altschul *et al.*, 1990, *supra*). The well-known Smith Waterman algorithm may also be used to determine identity.

[0087] For example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, WI), two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the "matched span," as determined by the algorithm). A gap opening penalty (which is calculated as 3X the average diagonal; the "average diagonal" is the average of the diagonal of the comparison matrix being used; the "diagonal" is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 0.1X the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix is also used by the algorithm (*see Dayhoff et al.*, *5 Atlas of Protein Sequence and Structure* (Supp. 3 1978)(PAM250 comparison matrix); Henikoff *et al.*, 1992, *Proc. Natl. Acad. Sci USA* 89:10915-19 (BLOSUM 62 comparison matrix)). The particular choices to be made with regard to algorithms, gap opening penalties, gap extension penalties,

comparison matrices, and thresholds of similarity will be readily apparent to those of skill in the art and will depend on the specific comparison to be made.

[0088] Related peptides also include derivatives of the OGF peptides defined and/or disclosed herein, wherein the variant retains some of or all of at least one OGF activity of the parent peptide. The derivative may also exhibit an increase in at least one OGF activity of the parent peptide. Chemical alterations of OGF peptide derivatives include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, T. E. Creighton, *Proteins, Structure and Molecular Properties*, 2nd ed., W.H. Freeman and Company, New York (1993); *Posttranslational Covalent Modification of Proteins*, B. C. Johnson, ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., *Meth. Enzymol* 182:626-46 (1990); Rattan et al., *Ann. N.Y. Acad. Sci.* 663:48-62, 1992).

[0089] OGF peptide derivatives also include molecules formed by the deletion of one or more chemical groups from the parent peptide. Methods for preparing chemically modified derivatives of the OGF peptides defined and/or disclosed herein are known to one of skill in the art.

[0090] In some embodiments of the invention, the OGF peptides may be modified with one or more methyl or other lower alkyl groups at one or more positions of the OGF peptide sequence. Examples of such groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, etc. In certain preferred embodiments, arginine, lysine, and histidine residues of the OGF peptides are modified with methyl or other lower alkyl groups.

[0091] In other embodiments of the invention, the OGF peptides may be modified with one or more glycoside moieties relative to the parent peptide. Although any glycoside can be used, in certain preferred embodiments the OGF peptide is modified by introduction of a monosaccharide, a disaccharide, or a trisaccharide or it may contain a glycosylation sequence found in natural peptides or proteins in any mammal. The saccharide may be

introduced at any position, and more than one glycoside may be introduced. Glycosylation may occur on a naturally occurring amino acid residue in the OGF peptide, or alternatively, an amino acid may be substituted with another for modification with the saccharide.

[0092] Glycosylated OGF peptides may be prepared using conventional Fmoc chemistry and solid phase peptide synthesis techniques, *e.g.*, on resin, where the desired protected glycoamino acids are prepared prior to peptide synthesis and then introduced into the peptide chain at the desired position during peptide synthesis. Thus, the OGF peptide polymer conjugates may be conjugated *in vitro*. The glycosylation may occur before deprotection. Preparation of aminoacid glycosides is described in U.S. Patent No. 5,767,254, WO 2005/097158, and Doores, K., *et al.*, *Chem. Commun.*, 1401-1403, 2006, which are incorporated herein by reference in their entireties. For example, alpha and beta selective glycosylations of serine and threonine residues are carried out using the Koenigs-Knorr reaction and Lemieux's *in situ* anomerization methodology with Schiff base intermediates. Deprotection of the Schiff base glycoside is then carried out using mildly acidic conditions or hydrogenolysis. A composition, comprising a glycosylated OGF peptide conjugate made by stepwise solid phase peptide synthesis involving contacting a growing peptide chain with protected amino acids in a stepwise manner, wherein at least one of the protected amino acids is glycosylated, followed by water-soluble polymer conjugation, may have a purity of at least 95%, such as at least 97%, or at least 98%, of a single species of the glycosylated and conjugated OGF peptide.

[0093] Monosaccharides that may be used for introduction at one or more amino acid residues of the OGF peptides defined and/or disclosed herein include glucose (dextrose), fructose, galactose, and ribose. Additional monosaccharides suitable for use include glyceraldehydes, dihydroxyacetone, erythrose, threose, erythrulose, arabinose, lyxose, xylose, ribulose, xylulose, allose, altrose, mannose, N-Acetylneuraminic acid, fucose, N-Acetylgalactosamine, and N-Acetylglucosamine, as well as others. Glycosides, such as mono-, di-, and trisaccharides for use in modifying an OGF peptide, may be naturally occurring or may be synthetic. Disaccharides that may be used for introduction at one or more amino acid residues of the OGF peptides defined and/or disclosed herein include sucrose, lactose, maltose, trehalose, melibiose, and cellobiose, among others. Trisaccharides include acarbose, raffinose, and melezitose.

[0094] In further embodiments of the invention, the OGF peptides defined and/or disclosed herein may be chemically coupled to biotin. The biotin/therapeutic peptide molecules can then to bind to avidin.

[0095] As previously noted, modifications may be made to the OGF peptides defined and/or disclosed herein that do not alter, or only partially abrogate, the properties and activities of these OGF peptides. In some instances, modifications may be made that result in an increase in OGF activity. Thus, included in the scope of the invention are modifications to the OGF peptides disclosed herein, including in Table 1, that retain at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, and any range derivable therein, such as, for example, at least 70% to at least 80%, and more preferably at least 81% to at least 90%; or even more preferably, between at least 91% and at least 99% of the OGF activity relative to the unmodified OGF peptide. Also included in the scope of the invention are modification to the OGF peptides disclosed herein, including in Table 1, that have greater than 100%, greater than 110%, greater than 125%, greater than 150%, greater than 200%, or greater than 300%, or greater than 10-fold or greater than 100-fold, and any range derivable therein, of the OGF activity relative to the unmodified OGF peptide.

[0096] The level of OGF activity of a given OGF peptide, or a modified OGF peptide, may be determined by any suitable *in vivo* or *in vitro* assay. For example, OGF activity may be assayed in cell culture, or by clinical evaluation, EC₅₀ assays, IC₅₀ assays, or dose response curves. *In vitro* or cell culture assays, for example, are commonly available and known to one of skill in the art for many OGF peptides as disclosed herein, including in Table 1. It will be understood by one of skill in the art that the percent activity of a modified OGF peptide relative to its unmodified parent can be readily ascertained through a comparison of the activity of each as determined through the assays disclosed herein or as known to one of skill in the art.

[0097] One of skill in the art will be able to determine appropriate modifications to the OGF peptides defined and/or disclosed herein, including those disclosed herein, including in Table 1. For identifying suitable areas of the OGF peptides that may be changed without abrogating their OGF activities, one of skill in the art may target areas not believed to be essential for activity. For example, when similar peptides with comparable activities exist

from the same species or across other species, one of skill in the art may compare those amino acid sequences to identify residues that are conserved among similar peptides. It will be understood that changes in areas of an OGF peptide that are not conserved relative to similar peptides would be less likely to adversely affect the therapeutic activity. One skilled in the art would also know that, even in relatively conserved regions, one may substitute chemically similar amino acids while retaining OGF activity. Therefore, even areas that may be important for biological activity and/or for structure may be subject to amino acid substitutions without destroying the OGF activity or without adversely affecting the peptide structure.

[0098] Additionally, as appropriate, one of skill in the art can review structure-function studies identifying residues in similar peptides that are important for activity or structure. In view of such a comparison, one can predict the importance of an amino acid residue in an OGF peptide that corresponds to an amino acid residue that is important for activity or structure in similar peptides. One of skill in the art may opt for amino acid substitutions within the same class of amino acids for such predicted important amino acid residues of the OGF peptides.

[0099] Also, as appropriate, one of skill in the art can also analyze the three-dimensional structure and amino acid sequence in relation to that structure in similar peptides. In view of such information, one of skill in the art may predict the alignment of amino acid residues of an OGF peptide with respect to its three dimensional structure. One of skill in the art may choose not to make significant changes to amino acid residues predicted to be on the surface of the peptide, since such residues may be involved in important interactions with other molecules. Moreover, one of skill in the art may generate variants containing a single amino acid substitution at each amino acid residue for test purposes. The variants could be screened using OGF activity assays known to those with skill in the art. Such variants could be used to gather information about suitable modifications. For example, where a change to a particular amino acid residue resulted in abrogated, undesirably reduced, or unsuitable activity, variants with such a modification would be avoided. In other words, based on information gathered from routine experimentation, one of skill in the art can readily determine the amino acids where further modifications should be avoided either alone or in combination with other modifications.

[00100] One of skill in the art may also select suitable modifications based on secondary structure predication. A number of scientific publications have been devoted to the prediction of secondary structure. See Moulton, 1996, *Curr. Opin. Biotechnol.* 7:422-27;

Chou *et al.*, 1974, *Biochemistry* 13:222-45; Chou *et al.*, 1974, *Biochemistry* 113:211-22; Chou *et al.*, 1978, *Adv. Enzymol. Relat. Areas Mol. Biol.* 47:45-48; Chou *et al.*, 1978, *Ann. Rev. Biochem.* 47:251-276; and Chou *et al.*, 1979, *Biophys. J.* 26:367-84. Moreover, computer programs are currently available to assist with predicting secondary structure. One method of predicting secondary structure is based upon homology modeling. For example, two peptides or proteins which have a sequence identity of greater than 30%, or similarity greater than 40%, often have similar structural topologies. Recent growth of the protein structural database (PDB, <http://www.rcsb.org/pdb/home/home.do>) has provided enhanced predictability of secondary, tertiary, and quarternary structure, including the potential number of folds within the structure of a peptide or protein. See Holm *et al.*, 1999, *Nucleic Acids Res.* 27:244-47. It has been suggested that there are a limited number of folds in a given peptide or protein and that once a critical number of structures have been resolved, structural prediction will become dramatically more accurate (Brenner *et al.*, 1997, *Curr. Opin. Struct. Biol.* 7:369-76).

[00101] Additional methods of predicting secondary structure include "threading" (Jones, 1997, *Curr. Opin. Struct. Biol.* 7:377-87; Sippl *et al.*, 1996, *Structure* 4:15-19), "profile analysis" (Bowie *et al.*, 1991, *Science*, 253:164-70; Gribskov *et al.*, 1990, *Methods Enzymol.* 183:146-59; Gribskov *et al.*, 1987, *Proc. Nat. Acad. Sci. U.S.A.* 84:4355-58), and "evolutionary linkage" (See Holm *et al.*, *supra*, and Brenner *et al.*, *supra*).

OGF Peptide Conjugates

[00102] As described above, a conjugate of the invention comprises a water-soluble polymer covalently attached (either directly or through a spacer moiety or linker) to an OGF peptide. Typically, for any given conjugate, there will be about one to five water-soluble polymers covalently attached to an OGF peptide (wherein for each water-soluble polymer, the water-soluble polymer can be attached either directly to the OGF peptide or through a spacer moiety).

[00103] To elaborate, an OGF peptide conjugate of the invention typically has about 1, 2, 3, or 4 water-soluble polymers individually attached to an OGF peptide. That is to say, in certain embodiments, a conjugate of the invention will possess about 4 water-soluble polymers individually attached to an OGF peptide, or about 3 water-soluble polymers individually attached to an OGF peptide, or about 2 water-soluble polymers individually attached to an OGF peptide, or about 1 water-soluble polymer attached to an OGF peptide.

The structure of each of the water-soluble polymers attached to the OGF peptide may be the same or different. One OGF peptide conjugate in accordance with the invention is one having a water-soluble polymer releasably attached to the OGF peptide, particularly at the *N*-terminus of the OGF peptide. Another OGF peptide conjugate in accordance with the invention is one having a water-soluble polymer stably attached to the OGF peptide, particularly at the *N*-terminus of the OGF peptide. Another OGF peptide conjugate is one having a water-soluble polymer releasably attached to the OGF peptide, particularly at the *C*-terminus of the OGF peptide. Another OGF peptide conjugate in accordance with the invention is one having a water-soluble polymer stably attached to the OGF peptide, particularly at the *C*-terminus of the OGF peptide. Other OGF peptide conjugates in accordance with the invention are those having a water-soluble polymer releasably or stably attached to an amino acid within the OGF peptide. Additional water-soluble polymers may be releasably or stably attached to other sites on the OGF peptide, *e.g.*, such as one or more additional sites. For example, an OGF peptide conjugate having a water-soluble polymer releasably attached to the *N*-terminus may additionally possess a water-soluble polymer stably attached to a lysine residue. In one embodiment, one or more amino acids may be inserted, at the *N*- or *C*-terminus, or within the peptide to releasably or stably attach a water soluble polymer. One preferred embodiment of the present invention is a mono-OGF peptide polymer conjugate, *i.e.*, an OGF peptide having one water-soluble polymer covalently attached thereto. In an even more preferred embodiment, the water-soluble polymer is one that is attached to the OGF peptide at its *N*-terminus.

[00104] In another embodiment of the invention, an OGF peptide polymer conjugate of the invention is absent a metal ion, *i.e.*, the OGF peptide is not chelated to a metal ion.

[00105] For the OGF peptide polymer conjugates described herein, the OGF peptide may optionally possess one or more *N*-methyl substituents. Alternatively, for the OGF peptide polymer conjugates described herein, the OGF peptide may be glycosylated, *e.g.*, having a mono- or disaccharide, or naturally-occurring amino acid glycosylation covalently attached to one or more sites thereof.

[00106] As discussed herein, the compounds of the present invention may be made by various methods and techniques known and available to those skilled in the art.

The Water-Soluble Polymer

[00107] A conjugate of the invention comprises an OGF peptide attached, stably or releasably, to a water-soluble polymer. The water-soluble polymer is typically hydrophilic, nonpeptidic, and biocompatible. A substance is considered biocompatible if the beneficial effects associated with use of the substance alone or with another substance (*e.g.*, an active agent such as an OGF peptide) in connection with living tissues (*e.g.*, administration to a patient) outweighs any deleterious effects as evaluated by a clinician, *e.g.*, a physician. A substance is considered nonimmunogenic if the intended use of the substance *in vivo* does not produce an undesired immune response (*e.g.*, the formation of antibodies) or, if an immune response is produced, that such a response is not deemed clinically significant or important as evaluated by a clinician. Typically, the water-soluble polymer is hydrophilic, biocompatible and nonimmunogenic.

[00108] Further the water-soluble polymer is typically characterized as having from 2 to about 300 termini, preferably from 2 to 100 termini, and more preferably from about 2 to 50 termini. Examples of such polymers include, but are not limited to, poly(alkylene glycols) such as polyethylene glycol (PEG), poly(propylene glycol) ("PPG"), copolymers of ethylene glycol and propylene glycol and the like, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(α -hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, poly(N-acryloylmorpholine), and combinations of any of the foregoing, including copolymers and terpolymers thereof.

[00109] The water-soluble polymer is not limited to a particular structure and may possess a linear architecture (*e.g.*, alkoxy PEG or bifunctional PEG), or a non-linear architecture, such as branched, forked, multi-armed (*e.g.*, PEGs attached to a polyol core), or dendritic (*i.e.* having a densely branched structure with numerous end groups). Moreover, the polymer subunits can be organized in any number of different patterns and can be selected, *e.g.*, from homopolymer, alternating copolymer, random copolymer, block copolymer, alternating tripolymer, random tripolymer, and block tripolymer.

[00110] One particularly preferred type of water-soluble polymer is a polyalkylene oxide, and in particular, polyethylene glycol (or PEG). Generally, a PEG used to prepare an OGF peptide polymer conjugate of the invention is "activated" or reactive. That is to say, the activated PEG (and other activated water-soluble polymers collectively referred to herein as "polymeric reagents") used to form an OGF peptide conjugate comprises an activated

functional group suitable for coupling to a desired site or sites on the OGF peptide. Thus, a polymeric reagent for use in preparing an OGF peptide conjugate includes a functional group for reaction with the OGF peptide.

[00111] Representative polymeric reagents and methods for conjugating such polymers to an active moiety are known in the art, and are, *e.g.*, described in Harris, J.M. and Zalipsky, S., eds, *Poly(ethylene glycol), Chemistry and Biological Applications*, ACS, Washington, 1997; Veronese, F., and J.M Harris, eds., *Peptide and Protein PEGylation*, Advanced Drug Delivery Reviews, 54(4); 453-609 (2002); Zalipsky, S., *et al.*, "Use of Functionalized Poly(Ethylene Glycols) for Modification of Polypeptides" in *Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications*, J. M. Harris, ed., Plenus Press, New York (1992); Zalipsky (1995) *Advanced Drug Reviews* 16:157-182, and in Roberts, *et al.*, *Adv. Drug Delivery Reviews*, 54, 459-476 (2002).

[00112] Additional PEG reagents suitable for use in forming a conjugate of the invention, and methods of conjugation are described in the Pasut. G., *et al.*, *Expert Opin. Ther. Patents* (2004), 14(5). PEG reagents suitable for use in the present invention also include those available from NOF Corporation, as described generally on the NOF website (<http://nofamerica.net/store/>). Products listed therein and their chemical structures are expressly incorporated herein by reference. Additional PEGs for use in forming an OGF peptide conjugate of the invention include those available from Polypure (Norway) and from QuantaBioDesign LTD (Ohio), where the contents of their catalogs with respect to available PEG reagents are expressly incorporated herein by reference. In addition, water soluble polymer reagents useful for preparing peptide conjugates of the invention can be prepared synthetically. Descriptions of the water soluble polymer reagent synthesis can be found in, for example, U.S. Patent Nos. 5,252,714, 5,650,234, 5,739,208, 5,932,462, 5,629,384, 5,672,662, 5,990,237, 6,448,369, 6,362,254, 6,495,659, 6,413,507, 6,376,604, 6,348,558, 6,602,498, and 7,026,440.

[00113] Typically, the weight-average molecular weight of the water-soluble polymer in the conjugate is from about 100 Daltons to about 150,000 Daltons. Exemplary ranges include weight-average molecular weights in the range of from about 250 Daltons to about 80,000 Daltons, from 500 Daltons to about 80,000 Daltons, from about 500 Daltons to about 65,000 Daltons, from about 500 Daltons to about 40,000 Daltons, from about 750 Daltons to about 40,000 Daltons, from about 1000 Daltons to about 30,000 Daltons. In a preferred embodiment, the weight average molecular weight of the water-soluble polymer in the conjugate ranges from about 1000 Daltons to about 10,000 Daltons. In certain other

preferred embodiments, the range is from about 1000 Daltons to about 5000 Daltons, from about 5000 Daltons to about 10,000 Daltons, from about 2500 Daltons to about 7500 Daltons, from about 1000 Daltons to about 3000 Daltons, from about 3000 Daltons to about 7000 Daltons, or from about 7000 Daltons to about 10,000 Daltons. In a further preferred embodiment, the weight average molecular weight of the water-soluble polymer in the conjugate ranges from about 20,000 Daltons to about 40,000 Daltons. In other preferred embodiments, the range is from about 20,000 Daltons to about 30,000 Daltons, from about 30,000 Daltons to about 40,000 Daltons, from about 25,000 Daltons to about 35,000 Daltons, from about 20,000 Daltons to about 26,000 Daltons, from about 26,000 Daltons to about 34,000 Daltons, or from about 34,000 Daltons to about 40,000 Daltons.

[00114] For any given water-soluble polymer, a molecular weight in one or more of these ranges is typical. Generally, an OGF peptide conjugate in accordance with the invention, when intended for subcutaneous or intravenous administration, will comprise a PEG or other suitable water-soluble polymer having a weight average molecular weight of about 20,000 Daltons or greater, while an OGF peptide conjugate intended for pulmonary administration will generally, although not necessarily, comprise a PEG polymer having a weight average molecular weight of about 20,000 Daltons or less.

[00115] Exemplary weight-average molecular weights for the water-soluble polymer include about 100 Daltons, about 200 Daltons, about 300 Daltons, about 400 Daltons, about 500 Daltons, about 600 Daltons, about 700 Daltons, about 750 Daltons, about 800 Daltons, about 900 Daltons, about 1,000 Daltons, about 1,500 Daltons, about 2,000 Daltons, about 2,200 Daltons, about 2,500 Daltons, about 3,000 Daltons, about 4,000 Daltons, about 4,400 Daltons, about 4,500 Daltons, about 5,000 Daltons, about 5,500 Daltons, about 6,000 Daltons, about 7,000 Daltons, about 7,500 Daltons, about 8,000 Daltons, about 9,000 Daltons, about 10,000 Daltons, about 11,000 Daltons, about 12,000 Daltons, about 13,000 Daltons, about 14,000 Daltons, about 15,000 Daltons, about 20,000 Daltons, about 22,500 Daltons, about 25,000 Daltons, about 30,000 Daltons, about 35,000 Daltons, about 40,000 Daltons, about 45,000 Daltons, about 50,000 Daltons, about 55,000 Daltons, about 60,000 Daltons, about 65,000 Daltons, about 70,000 Daltons, and about 75,000 Daltons.

[00116] Branched versions of the water-soluble polymer (*e.g.*, a branched 40,000 Dalton water-soluble polymer comprised of two 20,000 Dalton polymers or the like) having a total molecular weight of any of the foregoing can also be used. In one or more particular embodiments, depending upon the other features of the subject OGF peptide polymer


conjugate, the conjugate is one that does not have one or more attached PEG moieties having a weight-average molecular weight of less than about 6,000 Daltons.

[00117] In instances in which the water-soluble polymer is a PEG, the PEG will typically comprise a number of (OCH₂CH₂) monomers. As used herein, the number of repeat units is typically identified by the subscript "n" in, for example, "(OCH₂CH₂)_n." Thus, the value of (n) typically falls within one or more of the following ranges: from 2 to about 3400, from about 100 to about 2300, from about 100 to about 2270, from about 136 to about 2050, from about 225 to about 1930, from about 450 to about 1930, from about 1200 to about 1930, from about 568 to about 2727, from about 660 to about 2730, from about 795 to about 2730, from about 795 to about 2730, from about 909 to about 2730, and from about 1,200 to about 1,900. Preferred ranges of n include from about 10 to about 700, and from about 10 to about 1800. For any given polymer in which the molecular weight is known, it is possible to determine the number of repeating units (i.e., "n") by dividing the total weight-average molecular weight of the polymer by the molecular weight of the repeating monomer.

[00118] With regard to the molecular weight of the water-soluble polymer, in one or more embodiments of the invention, depending upon the other features of the particular OGF peptide conjugate, the conjugate comprises an OGF peptide covalently attached to a water-soluble polymer having a molecular weight greater than about 2,000 Daltons.

[00119] A polymer for use in the invention may be end-capped, that is, a polymer having at least one terminus capped with a relatively inert group, such as a lower alkoxy group (i.e., a C₁₋₆ alkoxy group) or a hydroxyl group. One frequently employed end-capped polymer is methoxy-PEG (commonly referred to as mPEG), wherein one terminus of the polymer is a methoxy (-OCH₃) group. The -PEG- symbol used in the foregoing generally represents the following structural unit: -CH₂CH₂O-(CH₂CH₂O)_n-CH₂CH₂-, where (n) generally ranges from about zero to about 4,000.


[00120] Multi-armed or branched PEG molecules, such as those described in U.S. Patent No. 5,932,462, are also suitable for use in the present invention. For example, the PEG may be described generally according to the structure:



where poly_a and poly_b are PEG backbones (either the same or different), such as methoxy poly(ethylene glycol); R'' is a non-reactive moiety, such as H, methyl or a PEG backbone;

X^5 , when present, is a spacer moiety; X^6 , when present, is a spacer moiety; X^7 , when present, is a spacer moiety; X^8 , when present, is a spacer moiety; R^5 is a branching moiety; and Z is a reactive group for coupling to an OGF peptide, optionally via an intervening spacer. POLY¹ and POLY² in the preceding branched polymer structure may be different or identical, *i.e.*, are of the same polymer type (structure) and molecular weight.

[00123] A preferred branched polymer falling into the above classification suitable for use in the present invention is:



where (m) is 2 to 4000, and (f) is 0 to 6 and (n) is 0 to 20.


[00124] Branched polymers suitable for preparing a conjugate of the invention also include those represented more generally by the formula R(POLY)_y, where R is a central or core molecule from which extends 2 or more POLY arms such as PEG. The variable y represents the number of POLY arms, where each of the polymer arms can independently be end-capped or alternatively, possess a reactive functional group at its terminus. A more explicit structure in accordance with this embodiment of the invention possesses the structure, R(POLY-Z)_y, where each Z is independently an end-capping group or a reactive group, *e.g.*, suitable for reaction with an OGF peptide. In yet a further embodiment when Z is a reactive group, upon reaction with an OGF peptide, the resulting linkage can be hydrolytically stable, or alternatively, may be degradable, *i.e.*, hydrolyzable. Typically, at least one polymer arm possesses a terminal functional group suitable for reaction with, *e.g.*, an OGF peptide. Branched PEGs such as those represented generally by the formula, R(PEG)_y above possess 2 polymer arms to about 300 polymer arms (*i.e.*, n ranges from 2 to about 300). Preferably, such branched PEGs typically possess from 2 to about 25 polymer arms, such as from 2 to about 20 polymer arms, from 2 to about 15 polymer arms, or from 3 to about 15 polymer arms. Multi-armed polymers include those having 3, 4, 5, 6, 7 or 8 arms.

[00125] Core molecules in branched PEGs as described above include polyols, which are then further functionalized. Such polyols include aliphatic polyols having from 1 to 10 carbon atoms and from 1 to 10 hydroxyl groups, including ethylene glycol, alkane diols, alkyl glycols, alkylidene alkyl diols, alkyl cycloalkane diols, 1,5-decalindiol, 4,8-

bis(hydroxymethyl)tricyclodecane, cycloalkylidene diols, dihydroxyalkanes, trihydroxyalkanes, and the like. Cycloaliphatic polyols may also be employed, including straight chained or closed-ring sugars and sugar alcohols, such as mannitol, sorbitol, inositol, xylitol, quebrachitol, threitol, arabitol, erythritol, adonitol, ducitol, facose, ribose, arabinose, xylose, lyxose, rhamnose, galactose, glucose, fructose, sorbose, mannose, pyranose, altrose, talose, tagitose, pyranosides, sucrose, lactose, maltose, and the like. Additional aliphatic polyols include derivatives of glyceraldehyde, glucose, ribose, mannose, galactose, and related stereoisomers. Other core polyols that may be used include crown ether, cyclodextrins, dextrans and other carbohydrates such as starches and amylose. Typical polyols include glycerol, pentaerythritol, sorbitol, and trimethylolpropane.

[00126] As will be described in more detail in the linker section below, although any of a number of linkages can be used to covalently attach a polymer to an OGF peptide, in certain instances, the linkage is degradable, designated herein as L_D , that is to say, contains at least one bond or moiety that hydrolyzes under physiological conditions, e.g., an ester, hydrolyzable carbamate, carbonate, or other such group. In other instances, the linkage is hydrolytically stable.

[00127] Illustrative multi-armed PEGs having 3 arms, 4 arms, and 8 arms are known and are available commercially and/or can be prepared following techniques known to those skilled in the art. Multi-armed activated polymers for use in the method of the invention include those corresponding to the following structure, where E represents a reactive group suitable for reaction with a reactive group on the OGF peptide. In one or more embodiments, E is an -OH (for reaction with an OGF peptide carboxy group or equivalent), a carboxylic acid or equivalent (such as an active ester), a carbonic acid (for reaction with OGF peptide -OH groups), or an amino group.



[00128] In the structure above, PEG is $-(CH_2CH_2O)_nCH_2CH_2-$, and m is selected from 3, 4, 5, 6, 7, and 8. In certain embodiments, typical linkages are ester, carboxyl and hydrolyzable carbamate, such that the polymer-portion of the conjugate is hydrolyzed *in vivo*

to release the OGF peptide from the intact polymer conjugate. In such instances, the linker L is designated as L_D.

[00129] Alternatively, the polymer may possess an overall forked structure as described in U.S. Patent No. 6,362,254. This type of polymer segment is useful for reaction with two OGF peptide moieties, where the two OGF peptide moieties are positioned a precise or predetermined distance apart.

[00130] In any of the representative structures provided herein, one or more degradable linkages may additionally be contained in the polymer segment, POLY, to allow generation *in vivo* of a conjugate having a smaller PEG chain than in the initially administered conjugate. Appropriate physiologically cleavable (*i.e.*, releasable) linkages include but are not limited to ester, carbonate ester, carbamate, sulfate, phosphate, acyloxyalkyl ether, acetal, and ketal. Such linkages when contained in a given polymer segment will often be stable upon storage and upon initial administration.

[00131] The PEG polymer used to prepare an OGF peptide polymer conjugate may comprise a pendant PEG molecule having reactive groups, such as carboxyl or amino, covalently attached along the length of the PEG rather than at the end of the PEG chain(s). The pendant reactive groups can be attached to the PEG directly or through a spacer moiety, such as an alkylene group.


[00132] In certain embodiments, an OGF peptide polymer conjugate according to one aspect of the invention is one comprising an OGF peptide releasably attached, preferably at its N-terminus, to a water-soluble polymer. Hydrolytically degradable linkages, useful not only as a degradable linkage within a polymer backbone, but also, in the case of certain embodiments of the invention, for covalently attaching a water-soluble polymer to an OGF peptide, include: carbonate; imine resulting, for example, from reaction of an amine and an aldehyde (see, *e.g.*, Ouchi *et al.* (1997) *Polymer Preprints* 38(1):582-3); phosphate ester, formed, for example, by reacting an alcohol with a phosphate group; hydrazone, *e.g.*, formed by reaction of a hydrazide and an aldehyde; acetal, *e.g.*, formed by reaction of an aldehyde and an alcohol; orthoester, formed, for example, by reaction between a formate and an alcohol; and esters, and certain urethane (carbamate) linkages.


[00133] Illustrative PEG reagents for use in preparing a releasable OGF peptide conjugate in accordance with the invention are described in U.S. Patent Nos. 6,348,558, 5,612,460, 5,840,900, 5,880,131, and 6,376,470.

[00134] Additional PEG reagents for use in the invention include hydrolyzable and/or releasable PEGs and linkers such as those described in U.S. Patent Application Publication

No. 2006-0293499. In the resulting conjugate, the OGF peptide and the polymer are each covalently attached to different positions of the aromatic scaffold, *e.g.*, Fmoc or FMS structure, and are releasable under physiological conditions. Generalized structures corresponding to the polymers described therein are provided below.


[00135] For example, one such polymeric reagent comprises the following structure:



where POLY¹ is a first water-soluble polymer; POLY² is a second water-soluble polymer; X¹ is a first spacer moiety; X² is a second spacer moiety;  is an aromatic-containing moiety bearing an ionizable hydrogen atom, H_α; R¹ is H or an organic radical; R² is H or an organic radical; and (FG) is a functional group capable of reacting with an amino group of an active agent to form a releasable linkage, such as a carbamate linkage (such as N-succinimidyl, 1-benzotriazolyl, oxycarbonylimidazole, -O-C(O)-Cl, O-C(O)-Br, unsubstituted aromatic carbonate radicals and substituted aromatic carbonate radicals). The polymeric reagent can include one, two, three, four or more electron altering groups attached to the aromatic-containing moiety.

[00136] Preferred aromatic-containing moieties are bicyclic and tricyclic aromatic hydrocarbons. Fused bicyclic and tricyclic aromatics include pentalene, indene, naphthalene, azulene, heptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, fluorene, phenalene, phenanthrene, anthracene, and fluoranthene.


[00137] A preferred polymer reagent possesses the following structure,




where mPEG corresponds to CH₃O-(CH₂CH₂O)_nCH₂CH₂-, X¹ and X² are each independently a spacer moiety having an atom length of from about 1 to about 18 atoms, n ranges from 10 to 1800, p is an integer ranging from 1 to 8, R¹ is H or lower alkyl, R² is H or lower alkyl, and


Ar is an aromatic hydrocarbon, preferably a bicyclic or tricyclic aromatic hydrocarbon. FG is as defined above. Preferably, FG corresponds to an activated carbonate ester suitable for reaction with an amino group on OGF peptide. Preferred spacer moieties, X¹ and X², include -NH-C(O)-CH₂-O-, -NH-C(O)-(CH₂)_q-O-, -NH-C(O)-(CH₂)_q-C(O)-NH-, -NH-C(O)-(CH₂)_q-, and -C(O)-NH-, where q is selected from 2, 3, 4, and 5. Preferably, although not necessarily, the nitrogen in the preceding spacers is proximal to the PEG rather than to the aromatic moiety.

[00138] Another such branched (2-armed) polymeric reagent comprised of two electron altering groups comprises the following structure:




wherein each of POLY¹, POLY², X¹, X², R¹, R², , and (FG) is as defined immediately above, and R^{e1} is a first electron altering group; and R^{e2} is a second electron altering group. An electron altering group is a group that is either electron donating (and therefore referred to as an "electron donating group"), or electron withdrawing (and therefore referred to as an "electron withdrawing group"). When attached to the aromatic-containing moiety bearing an ionizable hydrogen atom, an electron donating group is a group having the ability to position electrons away from itself and closer to or within the aromatic-containing moiety. When attached to the aromatic-containing moiety bearing an ionizable hydrogen atom, an electron withdrawing group is a group having the ability to position electrons toward itself and away from the aromatic-containing moiety. Hydrogen is used as the standard for comparison in the determination of whether a given group positions electrons away or toward itself. Preferred electron altering groups include, but are not limited to, -CF₃, -CH₂CF₃, -CH₂C₆F₅, -CN, -NO₂, -S(O)R, -S(O)Aryl, -S(O₂)R, -S(O₂)Aryl, -S(O₂)OR, -S(O₂)OAryl, -S(O₂)NHR, -S(O₂)NHAryl, -C(O)R, -C(O)Aryl, -C(O)OR, -C(O)NHR, and the like, wherein R is H or an organic radical.

[00139] An additional branched polymeric reagent suitable for use in the present invention comprises the following structure:




where POLY¹ is a first water-soluble polymer; POLY² is a second water-soluble polymer; X¹ is a first spacer moiety; X² is a second spacer moiety; Ar¹ is a first aromatic moiety; Ar² is a second aromatic moiety; H_α is an ionizable hydrogen atom; R¹ is H or an organic radical; R² is H or an organic radical; and (FG) is a functional group capable of reacting with an amino group of OGF peptide to form a releasable linkage, such as carbamate linkage.

[00140] Another exemplary polymeric reagent comprises the following structure:




wherein each of POLY¹, POLY², X¹, X², Ar¹, Ar², H_α, R¹, R², and (FG) is as previously defined, and R^{e1} is a first electron altering group. While stereochemistry is not specifically shown in any structure provided herein, the provided structures contemplate both enantiomers, as well as compositions comprising mixtures of each enantiomer in equal amounts (*i.e.*, a racemic mixture) and unequal amounts.

[00141] Yet an additional polymeric reagent for use in preparing an OGF peptide conjugate possesses the following structure:




wherein each of POLY¹, POLY², X¹, X², Ar¹, Ar², H_α, R¹, R², and (FG) is as previously defined, and R^{e1} is a first electron altering group; and R^{e2} is a second electron altering group.

[00142] A preferred polymeric reagent comprises the following structure:




wherein each of POLY¹, POLY², X¹, X², R¹, R², H_α and (FG) is as previously defined, and, as can be seen from the structure above, the aromatic moiety is a fluorene. The POLY arms substituted on the fluorene can be in any position in each of their respective phenyl rings, *i.e.*, POLY¹-X¹- can be positioned at any one of carbons 1, 2, 3, and 4, and POLY²-X²- can be in any one of positions 5, 6, 7, and 8.

[00143] Yet another preferred fluorene-based polymeric reagent comprises the following structure:





wherein each of POLY¹, POLY², X¹, X², R¹, R², H_α and (FG) is as previously defined, and R^{e1} is a first electron altering group; and R^{e2} is a second electron altering group as described above.

[00144] Yet another exemplary polymeric reagent for conjugating to an OGF peptide comprises the following fluorene-based structure:




wherein each of POLY¹, POLY², X¹, X², R¹, R², H_α and (FG) is as previously defined, and R^{e1} is a first electron altering group; and R^{e2} is a second electron altering group.


[00145] Particular fluorene-based polymeric reagents for forming a releasable OGF peptide polymer conjugate in accordance with the invention include the following:



and



[00146] Still another exemplary polymeric reagent comprises the following structure:



wherein each of POLY¹, POLY², X¹, X², R¹, R², H_α and (FG) is as previously defined, and R^{e1} is a first electron altering group; and R^{e2} is a second electron altering group. Branched reagents suitable for preparing a releasable OGF peptide conjugate include N-{di(mPEG(20,000)oxymethylcarbonylamino)fluoren-9-ylmethoxycarbonyloxy}succinimide, N-[2,7 di(4mPEG(10,000)aminocarbonylbutyrylamino)fluoren-9 ylmethoxycarbonyloxy]-succinimide ("G2PEG2Fmoc_{20k}-NHS"), and PEG2-CAC-Fmoc_{4k}-BTC. Of course, PEGs of any molecular weight as set forth herein may be employed in the above structures, and the particular activating groups described above are not meant to be limiting in any respect, and may be substituted by any other suitable activating group suitable for reaction with a reactive group present on the OGF peptide.

[00147] Those of ordinary skill in the art will recognize that the foregoing discussion describing water-soluble polymers for use in forming an OGF peptide conjugate is by no means exhaustive and is merely illustrative, and that all polymeric materials having the qualities described above are contemplated. As used herein, the term "polymeric reagent" generally refers to an entire molecule, which can comprise a water-soluble polymer segment, as well as additional spacers and functional groups.


The Linkage

[00148] The particular linkage between the OGF peptide and the water-soluble polymer depends on a number of factors. Such factors include, for example, the particular linkage chemistry employed, the particular spacer moieties utilized, if any, the particular OGF peptide, the available functional groups within the OGF peptide (either for attachment to a polymer or conversion to a suitable attachment site), and the possible presence of additional reactive functional groups or absence of functional groups within the OGF peptide

due to modifications made to the peptide such as methylation and/or glycosylation, and the like.

[00149] In one or more embodiments of the invention, the linkage between the OGF peptide and the water-soluble polymer is a releasable linkage. That is, the water-soluble polymer is cleaved (either through hydrolysis, an enzymatic processes, or otherwise), thereby resulting in an unconjugated OGF peptide. Preferably, the releasable linkage is a hydrolytically degradable linkage, where upon hydrolysis, the OGF peptide, or a slightly modified version thereof, is released. The releasable linkage may result in the water-soluble polymer (and any spacer moiety) detaching from the OGF peptide *in vivo* (and *in vitro*) without leaving any fragment of the water-soluble polymer (and/or any spacer moiety or linker) attached to the OGF peptide. Exemplary releasable linkages include carbonate, carboxylate ester, phosphate ester, thiolester, anhydrides, acetals, ketals, acyloxyalkyl ether, imines, carbamates, and orthoesters. Such linkages can be readily formed by reaction of the OGF peptide and/or the polymeric reagent using coupling methods commonly employed in the art. Hydrolyzable linkages are often readily formed by reaction of a suitably activated polymer with a non-modified functional group contained within the OGF peptide. Preferred positions for covalent attachment of a water-soluble polymer include the N-terminal, the C-terminal, as well as the internal lysines. Preferred releasable linkages include carbamate and ester.

[00150] Generally speaking, a preferred OGF peptide conjugate of the invention will possess the following generalized structure:



where POLY is a water-soluble polymer such as any of the illustrative polymeric reagents provided in Tables 2-4 herein, X is a linker, and in some embodiments a hydrolyzable linkage (L_D), and k is an integer selected from 1, 2, and 3, and in some instances 4, 5, 6, 7, 8, 9 and 10. In the generalized structure above, where X is L_D , L_D refers to the hydrolyzable linkage per se (e.g., a carbamate or an ester linkage), while "POLY" is meant to include the polymer repeat units, e.g., $\text{CH}_3(\text{OCH}_2\text{CH}_2)_n\text{-}$, and OGF is used to describe OGF. In a preferred embodiment of the invention, at least one of the water-soluble polymer molecules is covalently attached to the N-terminus of OGF peptide. In one embodiment of the invention, k equals 1 and X is -O-C(O)-NH- , where the -NH- is part of the OGF peptide residue and represents an amino group thereof.

[00151] Although releasable linkages are exemplary, the linkage between the OGF peptide and the water-soluble polymer (or the linker moiety that is attached to the polymer) may be a hydrolytically stable linkage, such as an amide, a urethane (also known as carbamate), amine, thioether (also known as sulfide), or urea (also known as carbamide). One such embodiment of the invention comprises an OGF peptide having a water-soluble polymer such as PEG covalently attached at the N-terminus of OGF peptide. In such instances, alkylation of the N-terminal residue permits retention of the charge on the N-terminal nitrogen.

[00152] With regard to linkages, in one or more embodiments of the invention, a conjugate is provided that comprises an OGF peptide covalently attached at an amino acid residue, either directly or through a linker comprised of one or more atoms, to a water-soluble polymer.

[00153] The conjugates (as opposed to an unconjugated OGF peptide) may or may not possess a measurable degree of OGF peptide activity. That is to say, a conjugate in accordance with the invention will typically possess anywhere from about 0% to about 100% or more of the OGF activity of the unmodified parent OGF peptide. Typically, compounds possessing little or no OGF activity contain a releasable linkage connecting the polymer to the OGF peptide, so that regardless of the lack of OGF activity in the conjugate, the active parent molecule (or a derivative thereof having OGF activity) is released by cleavage of the linkage (*e.g.*, hydrolysis upon aqueous-induced cleavage of the linkage). Such activity may be determined using a suitable *in vivo* or *in vitro* model, depending upon the known activity of the particular moiety having OGF peptide activity employed.

[00154] Optimally, cleavage of a linkage is facilitated through the use of hydrolytically cleavable and/or enzymatically cleavable linkages such as urethane, amide, certain carbamate, carbonate or ester-containing linkages. In this way, clearance of the conjugate via cleavage of individual water-soluble polymer(s) can be modulated by selecting the polymer molecular size and the type of functional group for providing the desired clearance properties. In certain instances, a mixture of polymer conjugates is employed where the polymers possess structural or other differences effective to alter the release (*e.g.*, hydrolysis rate) of the OGF peptide, such that one can achieve a desired sustained delivery profile.

[00155] One of ordinary skill in the art can determine the proper molecular size of the polymer as well as the cleavable functional group, depending upon several factors including the mode of administration. For example, one of ordinary skill in the art, using routine experimentation, can determine a proper molecular size and cleavable functional group by

first preparing a variety of polymer-OGF peptide conjugates with different weight-average molecular weights, degradable functional groups, and chemical structures, and then obtaining the clearance profile for each conjugate by administering the conjugate to a patient and taking periodic blood and/or urine samples. Once a series of clearance profiles has been obtained for each tested conjugate, a conjugate or mixture of conjugates having the desired clearance profile(s) can be determined.

[00156] For conjugates possessing a hydrolytically stable linkage that couples the OGF peptide to the water-soluble polymer, the conjugate will typically possess a measurable degree of OGF activity. For instance, such conjugates are typically characterized as having an OGF activity satisfying one or more of the following percentages relative to that of the unconjugated OGF peptide: at least 2%, at least 5%, at least 10%, at least 15%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 100%, more than 105%, more than 10-fold, or more than 100-fold (when measured in a suitable model, such as those presented here and/or known in the art). Often, conjugates having a hydrolytically stable linkage (*e.g.*, an amide linkage) will possess at least some degree of the OGF activity of the unmodified parent OGF peptide.

[00157] Exemplary conjugates in accordance with the invention will now be described. Amino groups on an OGF peptide provide a point of attachment between the OGF peptide and the water-soluble polymer. For example, an OGF peptide may comprise one or more lysine residues, each lysine residue containing an ϵ -amino group that may be available for conjugation, as well as the amino terminus.







[00158] There are a number of examples of suitable water-soluble polymeric reagents useful for forming covalent linkages with available amines of an OGF peptide. Certain specific examples, along with the corresponding conjugates, are provided in Table 2 below. In the table, the variable (n) represents the number of repeating monomeric units and "OGF" represents an OGF peptide following conjugation to the water-soluble polymer. While each polymeric portion [*e.g.*, $(\text{OCH}_2\text{CH}_2)_n$ or $(\text{CH}_2\text{CH}_2\text{O})_n$] presented in Table 2 terminates in a "CH₃" group, other groups (*e.g.*, H or benzyl) can be substituted therefore.



















[00159] As will be clearly understood by one skilled in the art, for conjugates such as those set forth below resulting from reaction with an OGF peptide amino group, the amino group extending from the OGF peptide designation "~NH-OGF" represents the residue of the OGF peptide itself in which the ~NH- is an amino group of the OGF peptide. One preferred site of attachment for the polymeric reagents shown below is the N-terminus. Further, although the conjugates in Tables 2-4 herein illustrate a single water-soluble polymer

covalently attached to an OGF peptide, it will be understood that the conjugate structures on the right are meant to also encompass conjugates having more than one of such water-soluble polymer molecules covalently attached to OGF peptide, *e.g.*, 2, 3, or 4 water-soluble polymer molecules.

Table 2

Amine-Specific Polymeric Reagents and the OGF Peptide Conjugates Formed Therefrom







$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \begin{array}{c} \text{N} \\ \text{C} \\ \text{N} \end{array}$ <p>mPEG-Oxycarbonylimidazole Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Carbamate Linkage</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{O}-\text{C}_6\text{H}_4-\text{NO}_2$ <p>mPEG Nitrophenyl Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Carbamate Linkage</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{O}-\text{C}_6\text{H}_2(\text{Cl})_3$ <p>mPEG-Trichlorophenyl Carbonate Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Carbamate Linkage</p>
 <p>Fmoc-NHS Reagent</p>	 <p>Carbamate Linkage</p>
 <p>Fmoc-NHS Reagent</p>	 <p>Carbamate Linkage</p>
 <p>Fmoc-NHS Reagent</p>	 <p>Carbamate Linkage</p>

 <p>Fmoc-BTC Reagent</p>	 <p>Carbamate Linkage</p>
 <p>mPEG-Succinimidyl Reagent</p>	 <p>Amide Linkage</p>
 <p>Homobifunctional PEG-Succinimidyl Reagent</p>	 <p>Amide Linkages</p>
 <p>Heterobifunctional PEG-Succinimidyl Reagent</p>	 <p>Amide Linkage</p>
 <p>mPEG-Succinimidyl Reagent</p>	 <p>Amide Linkage</p>
 <p>mPEG-Succinimidyl Reagent</p>	 <p>Amide Linkage</p>
 <p>mPEG Succinimidyl Reagent</p>	 <p>Amide Linkage</p>
 <p>mPEG-Succinimidyl Reagent</p>	 <p>Amide Linkage</p>
 <p>mPEG-Benzotriazole Carbonate Reagent</p>	 <p>Carbamate Linkage</p>

$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\text{C}(=\text{O})-\text{C}_6\text{H}_4-\text{O}-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array}$ <p>mPEG-Succinimidyl Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\text{C}(=\text{O})-\text{C}_6\text{H}_4-\text{O}-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Carbamate Linkage</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}_6\text{H}_4-\text{O}-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array}$ <p>mPEG-Succinimidyl Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}_6\text{H}_4-\text{O}-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Amide Linkage</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array}$ <p>mPEG Succinimidyl Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{O}-\text{NH}-(\text{OGF})$ <p>Amide Linkage</p>
$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{C} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH} \end{array}$ <p>Branched mPEG2-N-Hydroxysuccinimide Reagent</p>	$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{C} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH} \end{array} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \text{NH}-(\text{OGF})$ <p>Amide Linkage</p>
$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH} \\ \\ \text{CH}_2 \\ \\ \text{CH}_2 \\ \\ \text{CH}_2 \\ \\ \text{CH}_2 \\ \\ \text{H} \end{array} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \text{C}-\text{NH}-\text{CH}_2-\text{CH} \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH} \end{array}$ <p>Branched mPEG2-Aldehyde Reagent</p>	$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH} \\ \\ \text{CH}_2 \\ \\ \text{CH}_2 \\ \\ \text{CH}_2 \\ \\ \text{CH}_2 \\ \\ \text{H} \end{array} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \text{C}-\text{NH}-\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF}) \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\text{NH} \end{array}$ <p>Secondary Amine Linkage</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2-\text{C}(=\text{O})-\text{O}-\underset{\text{CH}_3}{\text{CH}}-\text{CH}_2-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array}$ <p>mPEG-Succinimidyl Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2-\text{C}(=\text{O})-\text{O}-\underset{\text{CH}_3}{\text{CH}}-\text{CH}_2-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Amide Linkage</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array}$ <p>mPEG-Succinimidyl Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Amide Linkage</p>
$\begin{array}{c} \text{N} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \text{O}-\text{C}(=\text{O})-\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{O}-\text{C}(=\text{O})-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\underset{\text{CH}_3}{\text{CH}}-\text{O}-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \end{array}$ <p>Homobifunctional PEG-Succinimidyl Reagent</p>	$\begin{array}{c} \text{HN} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \text{O}-\text{C}(=\text{O})-\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{O}-\text{C}(=\text{O})-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{C}(=\text{O})-\underset{\text{CH}_3}{\text{CH}}-\text{O}-\text{C}(=\text{O})-\text{NH} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \end{array} \begin{array}{c} \diagup \text{O} \\ \diagdown \end{array} \text{NH}-(\text{OGF})$ <p>Amide Linkages</p>

$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array}$ <p>mPEG-Succinimidyl Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Amide Linkage</p>
$\begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array} \text{N}-\text{O}-\text{C}(=\text{O})-\underset{\text{CH}_3}{\text{CH}_2\text{CH}_2}-\text{(OCH}_2\text{CH}_2\text{)}_n-\text{O}-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array}$ <p>Homobifunctional PEG-Succinimidyl Propionate Reagent</p>	$\begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array} \text{NH}-(\text{OGF})-\text{CH}_2\text{CH}_2-\underset{\text{CH}_3}{\text{C}}-\text{(OCH}_2\text{CH}_2\text{)}_n-\text{O}-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Amide Linkages</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2-\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array}$ <p>mPEG-Succinimidyl Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2-\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Amide Linkage</p>
$\begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\text{C}(=\text{O})-\text{O}-\text{CH}_2-\text{HC}(\text{OCH}_2\text{CH}_2\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array}$ <p>Branched mPEG2-N-Hydroxysuccinimide Reagent</p>	$\begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\text{C}(=\text{O})-\text{O}-\text{CH}_2-\text{HC}(\text{OCH}_2\text{CH}_2\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-\text{C}(=\text{O})-\text{NH}-(\text{OGF}))$ <p>Amide Linkage</p>
$\begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\text{C}(=\text{O})-\text{O}-\text{CH}_2-\text{HC}(\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{O}-\text{N} \begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array}$ <p>Branched mPEG2-N-Hydroxysuccinimide Reagent</p>	$\begin{array}{c} \text{O} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{O} \end{array} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\text{C}(=\text{O})-\text{O}-\text{CH}_2-\text{HC}(\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{NH}-(\text{OGF}))$ <p>Amide Linkage</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{S} \begin{array}{c} \text{N} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{N} \end{array}$ <p>mPEG-Thioester Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{NH}-(\text{OGF})$ <p>Amide Linkage (typically to OGF moiety having an N-terminal cysteine or histidine)</p>
$\text{O}=\text{C}-\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{CH}=\text{O}$ <p>Homobifunctional PEG Propionaldehyde Reagent</p>	$\text{NH}-(\text{OGF})-\text{CH}_2\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkages</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{CH}=\text{O}$ <p>mPEG Propionaldehyde Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage</p>
$\text{O}=\text{C}-\text{HCCH}_2\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2\text{CH}_2-\text{CH}=\text{O}$ <p>Homobifunctional PEG Butyraldehyde Reagent</p>	$\text{NH}-(\text{OGF})-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkages</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2\text{CH}_2-\text{CH}=\text{O}$ <p>mPEG Butyraldehyde Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage</p>

$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{H}$ <p>mPEG Butyraldehyde Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage</p>
$\begin{array}{c} \overset{\text{O}}{\parallel}\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{H} \\ \\ \text{HN} \\ \\ (\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{H} \end{array}$ <p>Homobifunctional PEG Butyraldehyde Reagent</p>	$\begin{array}{c} \overset{\text{O}}{\parallel}\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF}) \\ \\ \text{HN} \\ \\ (\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF}) \end{array}$ <p>Secondary Amine Linkages</p>
$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{H} \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH} \\ \\ \text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{H} \end{array}$ <p>Branched mPEG2 Butyraldehyde Reagent</p>	$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{H} \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH} \\ \\ \text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF}) \end{array}$ <p>Secondary Amine Linkage</p>
$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\text{CH}_2 \\ \\ \text{HC}-\text{OCH}_2\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{H} \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\text{CH}_2 \end{array}$ <p>Branched mPEG2 Butyraldehyde Reagent</p>	$\begin{array}{c} \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\text{CH}_2 \\ \\ \text{HC}-\text{OCH}_2\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF}) \\ \\ \text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\text{CH}_2 \end{array}$ <p>Secondary Amine Linkage</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2-\overset{\text{OCH}_2\text{CH}_3}{\underset{ }{\text{C}}}-\text{OCH}_2\text{CH}_3$ <p>mPEG Acetal Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{C}=\text{O}$ <p>mPEG Piperidone Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{C}=\text{O}-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage (to a secondary carbon)</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-(\text{CH}_2)_{2.5}-\overset{\text{O}}{\parallel}\text{C}-\text{CH}_3$ <p>mPEG Methylketone Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-(\text{CH}_2)_{2.5}-\overset{\text{NH}-(\text{OGF})}{\underset{ }{\text{C}}}-\text{CH}_3$ <p>secondary amine linkage (to a secondary carbon)</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\overset{\text{O}}{\parallel}\text{S}-\text{CH}_2-\text{CF}_3$ <p>mPEG tresylate Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{C}=\text{O}$ <p>mPEG Maleimide Reagent (under certain reaction conditions such as pH > 8)</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{C}=\text{O}-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{C}=\text{O}$ <p>mPEG Maleimide Reagent (under certain reaction conditions such as pH > 8)</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{C}=\text{O}-\text{NH}-(\text{OGF})$ <p>Secondary Amine Linkage</p>

 <p>mPEG Maleimide Reagent (under certain reaction conditions such as pH > 8)</p>	 <p>Secondary Amine Linkage</p>
 <p>mPEG Forked Maleimide Reagent (under certain reaction conditions such as pH > 8)</p>	 <p>Secondary Amine Linkages</p>
 <p>branched mPEG2 Maleimide Reagent (under certain reaction conditions such as pH > 8)</p>	 <p>Secondary Amine Linkage</p>

Amine Conjugation and Resulting Conjugates


[00160] Conjugation of a polymeric reagent to an amine group of an OGF peptide can be accomplished by a variety of techniques. In one approach, an OGF peptide is conjugated to a polymeric reagent functionalized with an active ester such as a succinimidyl derivative (*e.g.*, an N-hydroxysuccinimide ester). In this approach, the polymeric reagent bearing the reactive ester is reacted with the OGF peptide in aqueous media under appropriate pH conditions, *e.g.*, from pHs ranging from about 3 to about 8, about 3 to about 7, or about 4 to about 6.5. Most polymer active esters can couple to a target peptide such as OGF peptide at physiological pH, *e.g.*, at 7.0. However, less reactive derivatives may require a different pH. Typically, activated PEGs can be attached to a peptide such as OGF peptide at pHs from about 7.0 to about 10.0 for covalent attachment to an internal lysine. Typically, lower pHs are used, *e.g.*, 4 to about 5.75, for preferential covalent attachment to the N-terminus. Thus, different reaction conditions (*e.g.*, different pHs or different temperatures) can result in the attachment of a water-soluble polymer such as PEG to different locations on the OGF peptide (*e.g.*, internal lysines versus the N-terminus). Coupling reactions can often be carried out at room temperature, although lower temperatures may be required for particularly labile OGF

peptide moieties. Reaction times are typically on the order of minutes, *e.g.*, 30 minutes, to hours, *e.g.*, from about 1 to about 36 hours), depending upon the pH and temperature of the reaction. N-terminal PEGylation, *e.g.*, with a PEG reagent bearing an aldehyde group, is typically conducted under mild conditions, pHs from about 5-10, for about 6 to 36 hours. Varying ratios of polymeric reagent to OGF peptide may be employed, *e.g.*, from an equimolar ratio up to a 10-fold molar excess of polymer reagent. Typically, up to a 5-fold molar excess of polymer reagent will suffice.

[00161] In certain instances, it may be preferable to protect certain amino acids from reaction with a particular polymeric reagent if site specific or site selective covalent attachment is desired using commonly employed protection/deprotection methodologies such as those well known in the art.

[00162] In an alternative approach to direct coupling reactions, the PEG reagent may be incorporated at a desired position of the OGF peptide during peptide synthesis. In this way, site-selective introduction of one or more PEGs can be achieved. See, *e.g.*, International Patent Publication No. WO 95/00162, which describes the site selective synthesis of conjugated peptides.

[00163] Exemplary conjugates that can be prepared using, for example, polymeric reagents containing a reactive ester for coupling to an amino group of OGF peptide, comprise the following alpha-branched structure:




where POLY is a water-soluble polymer, (a) is either zero or one; X¹, when present, is a spacer moiety comprised of one or more atoms; R¹ is hydrogen or an organic radical; and "~NH-OGF" represents a residue of an OGF peptide, where the underlined amino group represents an amino group of the OGF peptide.

[00164] With respect to the structure corresponding to that referred to in the immediately preceding paragraph, any of the water-soluble polymers provided herein can be defined as POLY, any of the spacer moieties provided herein can be defined as X¹ (when present), any of the organic radicals provided herein can be defined as R¹ (in instances where R¹ is not hydrogen), and any of the OGF peptides provided herein can be employed. In one or more embodiments corresponding to the structure referred to in the immediately preceding paragraph, POLY is a poly(ethylene glycol) such as H₃CO(CH₂CH₂O)_n-, wherein (n) is an

integer having a value of from 3 to 4000, more preferably from 10 to about 1800; (a) is one; X^1 is a C_{1-6} alkylene, such as one selected from methylene (*i.e.*, $-CH_2-$), ethylene (*i.e.*, $-CH_2-CH_2-$) and propylene (*i.e.*, $-CH_2-CH_2-CH_2-$); R^1 is H or lower alkyl such as methyl or ethyl; and OGF corresponds to any OGF peptide disclosed herein, including in Table 1.


[00165] Typical of another approach for conjugating an OGF peptide to a polymeric reagent is reductive amination. Typically, reductive amination is employed to conjugate a primary amine of an OGF peptide with a polymeric reagent functionalized with a ketone, aldehyde or a hydrated form thereof (*e.g.*, ketone hydrate and aldehyde hydrate). In this approach, the primary amine from the OGF peptide (*e.g.*, the N-terminus) reacts with the carbonyl group of the aldehyde or ketone (or the corresponding hydroxy-containing group of a hydrated aldehyde or ketone), thereby forming a Schiff base. The Schiff base, in turn, is then reductively converted to a stable conjugate through use of a reducing agent such as sodium borohydride or any other suitable reducing agent. Selective reactions (*e.g.*, at the N-terminus) are possible, particularly with a polymer functionalized with a ketone or an alpha-methyl branched aldehyde and/or under specific reaction conditions (*e.g.*, reduced pH).

[00166] Exemplary conjugates that can be prepared using, for example, polymeric reagents containing an aldehyde (or aldehyde hydrate) or ketone or (ketone hydrate) possess the following structure:



where POLY is a water-soluble polymer; (d) is either zero or one; X^2 , when present, is a spacer moiety comprised of one or more atoms; (b) is an integer having a value of one through ten; (c) is an integer having a value of one through ten; R^2 , in each occurrence, is independently H or an organic radical; R^3 , in each occurrence, is independently H or an organic radical; and "NH-OGF" represents a residue of an OGF peptide, where the underlined amino group represents an amino group of the OGF peptide.


[00167] Yet another illustrative conjugate of the invention possesses the structure:



where k ranges from 1 to 3, and n ranges from 10 to about 1800.


[00168] With respect to the structure corresponding to that referred to in immediately preceding paragraph, any of the water-soluble polymers provided herein can be defined as POLY, any of the spacer moieties provided herein can be defined as X² (when present), any of the organic radicals provided herein can be independently defined as R² and R³ (in instances where R² and R³ are independently not hydrogen), and any of the OGF moieties provided herein can be defined as an OGF peptide. In one or more embodiments of the structure referred to in the immediately preceding paragraph, POLY is a poly(ethylene glycol) such as H₃CO(CH₂CH₂O)_n-, wherein (n) is an integer having a value of from 3 to 4000, more preferably from 10 to about 1800; (d) is one; X¹ is amide [e.g., -C(O)NH-]; (b) is 2 through 6, such as 4; (c) is 2 through 6, such as 4; each of R² and R³ are independently H or lower alkyl, such as methyl when lower alkyl; and OGF is OGF peptide.

[00169] Another example of an OGF peptide conjugate in accordance with the invention has the following structure:






wherein each (n) is independently an integer having a value of from 3 to 4000, preferably from 10 to 1800; X² is as previously defined; (b) is 2 through 6; (c) is 2 through 6; R², in each occurrence, is independently H or lower alkyl; and "~NH-OGF" represents a residue of an OGF peptide, where the underlined amino group represents an amino group of the OGF peptide.

[00170] Additional OGF peptide polymer conjugates resulting from reaction of a water-soluble polymer with an amino group of OGF peptide are provided below. The following conjugate structures are releasable. One such structure corresponds to:




where mPEG is $\text{CH}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-$, n ranges from 10 to 1800, p is an integer ranging from 1 to 8, R^1 is H or lower alkyl, R^2 is H or lower alkyl, Ar is an aromatic hydrocarbon, such as a fused bicyclic or tricyclic aromatic hydrocarbon, X^1 and X^2 are each independently a spacer moiety having an atom length of from about 1 to about 18 atoms, $\sim\text{NH-OGF}$ is as previously described, and k is an integer selected from 1, 2, and 3. The value of k indicates the number of water-soluble polymer molecules attached to different sites on the OGF peptide. In a preferred embodiment, R^1 and R^2 are both H. The spacer moieties, X^1 and X^2 , preferably each contain one amide bond. In a preferred embodiment, X^1 and X^2 are the same. Preferred spacers, *i.e.*, X^1 and X^2 , include $-\text{NH-C(O)-CH}_2\text{-O-}$, $-\text{NH-C(O)-(CH}_2)_q\text{-O-}$, $-\text{NH-C(O)-(CH}_2)_q\text{-C(O)-NH-}$, $-\text{NH-C(O)-(CH}_2)_q-$, and $-\text{C(O)-NH-}$, where q is selected from 2, 3, 4, and 5. Although the spacers can be in either orientation, preferably, the nitrogen is proximal to the PEG rather than to the aromatic moiety. Illustrative aromatic moieties include pentalene, indene, naphthalene, indacene, acenaphthylene, and fluorene.


[00171] Particularly preferred conjugates of this type are provided below.





and



[00172] Additional OGF peptide conjugates resulting from covalent attachment to amino groups of OGF peptide that are also releasable include the following:




where X is either -O- or -NH-C(O)-, Ar₁ is an aromatic group, *e.g.*, *ortho*, *meta*, or *para*-substituted phenyl, and k is an integer selected from 1, 2, and 3. Particular conjugates of this type include:



where n ranges from about 10 to about 1800.


[00173] Additional releasable conjugates in accordance with the invention are prepared using water-soluble polymer reagents such as those described in U.S. Patent No. 6,214,966. Such water-soluble polymers result in a releasable linkage following conjugation, and possess at least one releasable ester linkage close to the covalent attachment to the active agent. The polymers generally possess the following structure, PEG-W-CO₂-NHS or an equivalent activated ester, where



and NHS is N-hydroxysuccinimidyl. Upon hydrolysis, the resulting released active agent, *e.g.*, OGF peptide, will possess a short tag resulting from hydrolysis of the ester functionality of the polymer reagent. Illustrative releasable conjugates of this type include: mPEG-O-(CH₂)_b-COOCH₂C(O)-NH-OGF peptide, and mPEG-O-(CH₂)_b-COO-CH(CH₃)-CH₂-C(O)-NH-OGF peptide, where the number of water-soluble polymers attached to OGF peptide can be anywhere from 1 to 4, or more preferably, from 1 to 3.

Carboxyl Coupling and Resulting Conjugates

[00174] Carboxyl groups represent another functional group that can serve as a point of attachment to the OGF peptide. The conjugate will have the following structure:



where OGF-C(O) ~ corresponds to a residue of an OGF peptide where the carbonyl is a carbonyl (derived from the carboxy group) of the OGF peptide, X is a spacer moiety, such as a heteroatom selected from O, N(H), and S, and POLY is a water-soluble polymer such as PEG, optionally terminating in an end-capping moiety.

[00175] The C(O)-X linkage results from the reaction between a polymeric derivative bearing a terminal functional group and a carboxyl-containing OGF peptide. As discussed above, the specific linkage will depend on the type of functional group utilized. If the polymer is end-functionalized or "activated" with a hydroxyl group, the resulting linkage will be a carboxylic acid ester and X will be O. If the polymer backbone is functionalized with a thiol group, the resulting linkage will be a thioester and X will be S. When certain multi-arm, branched or forked polymers are employed, the C(O)X moiety, and in particular the X moiety, may be relatively more complex and may include a longer linker structure.

[00176] Polymeric reagents containing a hydrazide moiety are also suitable for conjugation at a carbonyl. To the extent that the OGF peptide does not contain a carbonyl moiety, a carbonyl moiety can be introduced by reducing any carboxylic acid functionality (*e.g.*, the C-terminal carboxylic acid). Specific examples of polymeric reagents comprising a hydrazide moiety, along with the corresponding conjugates, are provided in Table 3, below. In addition, any polymeric reagent comprising an activated ester (*e.g.*, a succinimidyl group) can be converted to contain a hydrazide moiety by reacting the polymer activated ester with hydrazine (NH₂-NH₂) or tert-butyl carbamate [NH₂NHCO₂C(CH₃)₃]. In the table, the variable (n) represents the number of repeating monomeric units and "=C-OGF" represents a

residue of an OGF peptide following conjugation to the polymeric reagent were the underlined C is part of the OGF peptide. Optionally, the hydrazone linkage can be reduced using a suitable reducing agent. While each polymeric portion [e.g., (OCH₂CH₂)_n or (CH₂CH₂O)_n] presented in Table 3 terminates in a "CH₃" group, other groups (such as H and benzyl) can be substituted therefor.

Table 3

Carboxyl-Specific Polymeric Reagents and the OGF Peptide Conjugates Formed therefrom

Polymeric Reagent	Corresponding Conjugate
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{O}-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{O}-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\overset{\text{H}}{\text{N}}-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{S}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{S}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\text{NH}-\overset{\text{S}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\overset{\text{H}}{\text{N}}-\text{NH}-\overset{\text{S}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{NH}_2$ mPEG-Hydrazine Reagent	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-\text{N}=\text{C}-(\text{OGF})$ Hydrazone Linkage









Thiol Coupling and Resulting Conjugates















[00177] Thiol groups contained within the OGF peptide can serve as effective sites of attachment for the water-soluble polymer. The thiol groups contained in cysteine residues of the OGF peptide can be reacted with an activated PEG that is specific for reaction with thiol groups, *e.g.*, an N-maleimidyl polymer or other derivative, as described in, for example, U.S. Patent No. 5,739,208, WO 01/62827, and in Table 4 below. In certain embodiments, cysteine residues may be introduced in the OGF peptide and may be used to attach a water-soluble polymer.



[00178] Specific examples of the reagents themselves, along with the corresponding conjugates, are provided in Table 4 below. In the table, the variable (n) represents the number of repeating monomeric units and "~S-OGF" represents a residue of an OGF peptide following conjugation to the water-soluble polymer, where the S represents the residue of an OGF peptide thiol group. While each polymeric portion [*e.g.*, (OCH₂CH₂)_n or (CH₂CH₂O)_n] presented in Table 4 terminates in a "CH₃" group, other end-capping groups (such as H and benzyl) or reactive groups may be used as well.

Table 4


Thiol-Specific Polymeric Reagents and the OGF peptide Conjugates Formed Therefrom

Polymeric Reagent	Corresponding Conjugate
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{N}$  <p>mPEG Maleimide Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{N}$  <p>Thioether Linkage</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2\text{CH}_2-\text{N}$  <p>mPEG Maleimide Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2\text{CH}_2-\text{N}$  <p>Thioether Linkage</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{NH}-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{NH}-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2\text{CH}_2-\text{N}$  <p>mPEG Maleimide Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{C}(=\text{O})-\text{NH}-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{NH}-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2\text{CH}_2-\text{N}$  <p>Thioether Linkage</p>
 <p>Homobifunctional mPEG Maleimide Reagent</p>	 <p>Thioether Linkages</p>

Polymeric Reagent	Corresponding Conjugate
<p>$H_3C-(OCH_2CH_2)_n-O-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>mPEG Maleimide Reagent</p>	<p>$H_3C-(OCH_2CH_2)_n-O-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>Thioether Linkage</p>
<p>$H_3C-(OCH_2CH_2)_n-O-CH_2CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>mPEG Maleimide Reagent</p>	<p>$H_3C-(OCH_2CH_2)_n-O-CH_2CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>Thioether Linkage</p>
 <p>mPEG Maleimide Reagent</p>	 <p>Thioether Linkage</p>
<p>$H_3C-(OCH_2CH_2)_n-O-CH_2CH_2-C(=O)-NH-CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>mPEG Forked Maleimide Reagent</p>	<p>$H_3C-(OCH_2CH_2)_n-O-CH_2CH_2-C(=O)-NH-CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>Thioether Linkage</p>
<p>$H_3C-(OCH_2CH_2)_n-O-C(=O)-NH-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>branched mPEG2 Maleimide Reagent</p>	<p>$H_3C-(OCH_2CH_2)_n-O-C(=O)-NH-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>Thioether Linkage</p>
<p>$H_3C-(OCH_2CH_2)_n-NH-C(=O)-O-CH_2-CH_2-O-CH_2CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>branched mPEG2 Maleimide Reagent</p>	<p>$H_3C-(OCH_2CH_2)_n-NH-C(=O)-O-CH_2-CH_2-O-CH_2CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>Thioether Linkage</p>
<p>$H_3C-(OCH_2CH_2)_n-O-C(=O)-NH-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-C(=O)-NH-CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>Branched mPEG2 Forked Maleimide Reagent</p>	<p>$H_3C-(OCH_2CH_2)_n-O-C(=O)-NH-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-CH_2-C(=O)-NH-CH_2-CH_2-C(=O)-NH-CH_2CH_2-NH-C(=O)-CH_2CH_2-N$</p>  <p>Thioether Linkages</p>

Polymeric Reagent	Corresponding Conjugate
 <p data-bbox="167 488 790 524">Branched mPEG2 Forked Maleimide Reagent</p>	 <p data-bbox="829 488 1412 524">Thioether Linkages</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{S}(=\text{O})_2-\text{CH}=\text{CH}_2$ <p data-bbox="167 638 790 667">mPEG Vinyl Sulfone Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{S}(=\text{O})_2-\text{CH}_2-\text{CH}_2-\text{S}-(\text{OGF})$ <p data-bbox="829 638 1412 667">Thioether Linkage</p>
$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{NH}-\text{CH}_2-\text{CH}_2-\text{SH}$ <p data-bbox="167 750 790 779">mPEG Thiol Reagent</p>	$\text{H}_3\text{C}-(\text{OCH}_2\text{CH}_2)_n-\text{O}-\text{CH}_2\text{CH}_2-\text{C}(=\text{O})-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}-\text{S}-(\text{OGF})$ <p data-bbox="829 750 1412 779">Disulfide Linkage</p>
$\text{HS}-\text{CH}_2\text{CH}_2-\text{NH}-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2)_n-\text{C}(=\text{O})-\text{NH}-\text{CH}_2\text{CH}_2-\text{SH}$ <p data-bbox="167 862 790 891">Homobifunctional PEG Thiol Reagent</p>	$(\text{OGF})\text{S}-\text{S}-\text{CH}_2\text{CH}_2-\text{NH}-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-(\text{OCH}_2\text{CH}_2)_n-\text{C}(=\text{O})-\text{NH}-\text{CH}_2\text{CH}_2-\text{S}-\text{S}-(\text{OGF})$ <p data-bbox="829 862 1412 891">Disulfide Linkages</p>
$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-\text{S}-\text{S}-\text{C}_4\text{H}_4\text{N}$ <p data-bbox="167 985 790 1008">mPEG Disulfide Reagent</p>	$\text{H}_3\text{CO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-\text{S}-\text{S}-(\text{OGF})$ <p data-bbox="829 985 1412 1008">Disulfide Linkage</p>

[00179] With respect to conjugates formed from water-soluble polymers bearing one or more maleimide functional groups (regardless of whether the maleimide reacts with an amine or thiol group on the OGF peptide), the corresponding maleamic acid form(s) of the water-soluble polymer can also react with the OGF peptide. Under certain conditions (*e.g.*, a pH of about 7-9 and in the presence of water), the maleimide ring will "open" to form the corresponding maleamic acid. The maleamic acid, in turn, can react with an amine or thiol group of an OGF peptide. Exemplary maleamic acid-based reactions are schematically shown below. POLY represents the water-soluble polymer, and ~S-OGF represents a residue of an OGF peptide, where the S is derived from a thiol group of the OGF peptide.




[00180] Thiol PEGylation is specific for free thiol groups on the OGF peptide. Typically, a polymer maleimide is conjugated to a sulfhydryl-containing OGF peptide at pHs ranging from about 6-9 (*e.g.*, at 6, 6.5, 7, 7.5, 8, 8.5, or 9), more preferably at pHs from about 7-9, and even more preferably at pHs from about 7 to 8. Generally, a slight molar excess of polymer maleimide is employed, for example, a 1.5 to 15-fold molar excess, preferably a 2-fold to 10 fold molar excess. Reaction times generally range from about 15 minutes to several hours, *e.g.*, 8 or more hours, at room temperature. For sterically hindered sulfhydryl groups, required reaction times may be significantly longer. Thiol-selective conjugation is preferably conducted at pHs around 7. Temperatures for conjugation reactions are typically, although not necessarily, in the range of from about 0 °C to about 40 °C; conjugation is often carried out at room temperature or less. Conjugation reactions are often carried out in a buffer such as a phosphate or acetate buffer or similar system.

[00181] With respect to reagent concentration, an excess of the polymeric reagent is typically combined with the OGF peptide. The conjugation reaction is allowed to proceed until substantially no further conjugation occurs, which can generally be determined by monitoring the progress of the reaction over time.

[00182] Progress of the reaction can be monitored by withdrawing aliquots from the reaction mixture at various time points and analyzing the reaction mixture by SDS-PAGE or

MALDI-TOF mass spectrometry or any other suitable analytical method. Once a plateau is reached with respect to the amount of conjugate formed or the amount of unconjugated polymer remaining, the reaction is assumed to be complete. Typically, the conjugation reaction takes anywhere from minutes to several hours (*e.g.*, from 5 minutes to 24 hours or more). The resulting product mixture is preferably, but not necessarily purified, to separate out excess reagents, unconjugated reactants (*e.g.*, OGF peptide) undesired multi-conjugated species, and free or unreacted polymer. The resulting conjugates can then be further characterized using analytical methods such as MALDI, capillary electrophoresis, gel electrophoresis, and/or chromatography.

[00183] An illustrative OGF peptide conjugate formed by reaction with one or more OGF peptide thiol groups may possess the following structure:



where POLY is a water-soluble polymer, X is an optional linker, Z is a heteroatom selected from the group consisting of O, NH, and S, and Y is selected from the group consisting of C₂₋₁₀ alkyl, C₂₋₁₀ substituted alkyl, aryl, and substituted aryl, and ~S-OGF is a residue of an OGF peptide, where the S represents the residue of an OGF peptide thiol group. Such polymeric reagents suitable for reaction with an OGF peptide to result in this type of conjugate are described in U.S. Patent Application Publication No. 2005/0014903, which is incorporated herein by reference.

[00184] With respect to polymeric reagents suitable for reacting with an OGF peptide thiol group, those described here and elsewhere can be obtained from commercial sources. In addition, methods for preparing polymeric reagents are described in the literature.

Additional Conjugates and Features Thereof

[00185] As is the case for any OGF peptide polymer conjugate of the invention, the attachment between the OGF peptide and water-soluble polymer can be direct, wherein no intervening atoms are located between the OGF peptide and the polymer, or indirect, wherein one or more atoms are located between the OGF peptide and polymer. With respect to the indirect attachment, a "spacer moiety or linker" serves as a link between the OGF peptide and the water-soluble polymer. The one or more atoms making up the spacer moiety can include one or more of carbon atoms, nitrogen atoms, sulfur atoms, oxygen atoms, and combinations thereof. The spacer moiety can comprise an amide, secondary amine, carbamate, thioether, and/or disulfide group. Nonlimiting examples of specific spacer moieties (including "X", X¹


, X², and X³) include those selected from the group consisting of -O-, -S-, -S-S-, -C(O)-, -C(O)O-, -OC(O)-, -CH₂-C(O)O-, -CH₂-OC(O)-, -C(O)O-CH₂-, -OC(O)-CH₂-, -C(O)-NH-, -NH-C(O)-NH-, -O-C(O)-NH-, -C(S)-, -CH₂-, -CH₂-CH₂-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -O-CH₂-, -CH₂-O-, -O-CH₂-CH₂-, -CH₂-O-CH₂-, -CH₂-CH₂-O-, -O-CH₂-CH₂-CH₂-, -CH₂-O-CH₂-CH₂-, -CH₂-CH₂-O-CH₂-, -CH₂-CH₂-CH₂-O-, -O-CH₂-CH₂-CH₂-CH₂-, -CH₂-O-CH₂-CH₂-CH₂-, -CH₂-CH₂-O-CH₂-CH₂-, -CH₂-CH₂-CH₂-O-CH₂-, -CH₂-CH₂-CH₂-CH₂-O-, -C(O)-NH-CH₂-, -C(O)-NH-CH₂-CH₂-, -CH₂-C(O)-NH-CH₂-, -CH₂-CH₂-C(O)-NH-, -C(O)-NH-CH₂-CH₂-CH₂-, -CH₂-C(O)-NH-CH₂-CH₂-, -CH₂-CH₂-C(O)-NH-CH₂-, -CH₂-CH₂-CH₂-C(O)-NH-, -C(O)-NH-CH₂-CH₂-CH₂-CH₂-, -CH₂-C(O)-NH-CH₂-CH₂-CH₂-, -CH₂-CH₂-C(O)-NH-CH₂-CH₂-, -CH₂-CH₂-CH₂-C(O)-NH-CH₂-, -CH₂-CH₂-CH₂-C(O)-NH-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-C(O)-NH-, -C(O)-O-CH₂-, -CH₂-C(O)-O-CH₂-, -CH₂-CH₂-C(O)-O-CH₂-, -C(O)-O-CH₂-CH₂-, -NH-C(O)-CH₂-, -CH₂-NH-C(O)-CH₂-, -CH₂-CH₂-NH-C(O)-CH₂-, -NH-C(O)-CH₂-CH₂-, -CH₂-NH-C(O)-CH₂-CH₂-, -CH₂-CH₂-NH-C(O)-CH₂-CH₂-, -C(O)-NH-CH₂-, -O-C(O)-NH-CH₂-, -O-C(O)-NH-CH₂-CH₂-, -NH-CH₂-, -NH-CH₂-CH₂-, -CH₂-NH-CH₂-, -CH₂-CH₂-NH-CH₂-, -C(O)-CH₂-, -C(O)-CH₂-CH₂-, -CH₂-C(O)-CH₂-, -CH₂-CH₂-C(O)-CH₂-, -CH₂-CH₂-C(O)-CH₂-CH₂-, -CH₂-CH₂-C(O)-, -CH₂-CH₂-CH₂-C(O)-NH-CH₂-CH₂-NH-, -CH₂-CH₂-CH₂-C(O)-NH-CH₂-CH₂-NH-C(O)-, -CH₂-CH₂-CH₂-C(O)-NH-CH₂-CH₂-NH-C(O)-CH₂-, -CH₂-CH₂-CH₂-C(O)-NH-CH₂-CH₂-NH-C(O)-CH₂-CH₂-, -O-C(O)-NH-[CH₂]_h-(OCH₂CH₂)_j-, bivalent cycloalkyl group, -O-, -S-, an amino acid, -N(R⁶)-, and combinations of two or more of any of the foregoing, wherein R⁶ is H or an organic radical selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl and substituted aryl, (h) is zero to six, and (j) is zero to 20. Other specific spacer moieties have the following structures: -C(O)-NH-(CH₂)₁₋₆-NH-C(O)-, -NH-C(O)-NH-(CH₂)₁₋₆-NH-C(O)-, and -O-C(O)-NH-(CH₂)₁₋₆-NH-C(O)-, wherein the subscript values following each methylene indicate the number of methylenes contained in the structure, e.g., (CH₂)₁₋₆ means that the structure can contain 1, 2, 3, 4, 5 or 6 methylenes. Additionally, any of the above spacer moieties may further include an ethylene oxide oligomer chain comprising 1 to 20 ethylene oxide monomer units [*i.e.*, -(CH₂CH₂O)₁₋₂₀]. That is, the ethylene oxide oligomer chain can occur before or after the spacer moiety, and optionally in between any two atoms of a spacer moiety comprised of two or more atoms. Also, the oligomer chain would not be considered part of the spacer moiety if

the oligomer is adjacent to a polymer segment and merely represent an extension of the polymer segment.

[00186] As indicated above, in some instances the water-soluble polymer-(OGF) conjugate will include a non-linear water-soluble polymer. Such a non-linear water-soluble polymer encompasses a branched water-soluble polymer (although other non linear water-soluble polymers are also contemplated). Thus, in one or more embodiments of the invention, the conjugate comprises an OGF peptide covalently attached, either directly or through a spacer moiety comprised of one or more atoms, to a branched water-soluble polymer, at in a non-limiting example, an internal or *N*-terminal amine. As used herein, an internal amine is an amine that is not part of the *N*-terminal amino acid (meaning not only the *N*-terminal amine, but any amine on the side chain of the *N*-terminal amino acid).

[00187] Although such conjugates include a branched water-soluble polymer attached (either directly or through a spacer moiety) to an OGF peptide at an internal amino acid of the OGF peptide, additional branched water-soluble polymers can also be attached to the same OGF peptide at other locations as well. Thus, for example, a conjugate including a branched water-soluble polymer attached (either directly or through a spacer moiety) to an OGF peptide at an internal amino acid of the OGF peptide, can further include an additional branched water-soluble polymer covalently attached, either directly or through a spacer moiety comprised of one or more atoms, to the *N*-terminal amino acid residue, such as at the *N*-terminal amine.


[00188] One preferred branched water-soluble polymer comprises the following structure:



wherein each (n) is independently an integer having a value of from 3 to 4000, or more preferably, from about 10 to 1800.


[00189] Also forming part of the invention are multi-armed polymer conjugates comprising a polymer scaffold having 3 or more polymer arms each suitable for capable of covalent attachment of an OGF peptide.

Exemplary conjugates in accordance with this embodiment of the invention will generally comprise the following structure:




wherein R is a core molecule as previously described, POLY is a water-soluble polymer, X is a cleavable, *e.g.*, hydrolyzable linkage, and y ranges from about 3 to 15.

[00190] More particularly, such a conjugate may comprise the structure:



where m is selected from 3, 4, 5, 6, 7, and 8.

[00191] In yet a related embodiment, the OGF peptide conjugate may correspond to the structure:



where R is a core molecule as previously described, X is -NH-P-Z-C(O) P is a spacer, Z is -O-, -NH-, or -CH₂-, -O-OGF is a hydroxyl residue of an OGF peptide, and y is 3 to 15. Preferably, X is a residue of an amino acid.

Purification

[00192] The OGF peptide polymer conjugates described herein can be purified to obtain/isolate different conjugate species. Specifically, a product mixture can be purified to obtain an average of anywhere from one, two, or three or even more PEGs per OGF peptide. In one embodiment of the invention, preferred OGF peptide conjugates are mono-conjugates. The strategy for purification of the final conjugate reaction mixture will depend upon a number of factors, including, for example, the molecular weight of the polymeric reagent employed, the OGF peptide, and the desired characteristics of the product – *e.g.*, monomer, dimer, particular positional isomers, etc.

[00193] If desired, conjugates having different molecular weights can be isolated using gel filtration chromatography and/or ion exchange chromatography. Gel filtration chromatography may be used to fractionate different OGF peptide conjugates (*e.g.*, 1-mer, 2-mer, 3-mer, and so forth, wherein "1-mer" indicates one polymer molecule per OGF peptide, "2-mer" indicates two polymers attached to OGF peptide, and so on) on the basis of their differing molecular weights (where the difference corresponds essentially to the average molecular weight of the water-soluble polymer). While this approach can be used to separate PEG and other OGF peptide polymer conjugates having different molecular weights, this approach is generally ineffective for separating positional isomers having different polymer attachment sites within the OGF peptide. For example, gel filtration chromatography can be used to separate from each other mixtures of PEG 1-mers, 2-mers, 3-mers, and so forth, although each of the recovered PEG-mer compositions may contain PEGs attached to different reactive amino groups (*e.g.*, lysine residues) or other functional groups of the OGF peptide.

[00194] Gel filtration columns suitable for carrying out this type of separation include Superdex™ and Sephadex™ columns available from Amersham Biosciences (Piscataway, NJ). Selection of a particular column will depend upon the desired fractionation range desired. Elution is generally carried out using a suitable buffer, such as phosphate, acetate, or the like. The collected fractions may be analyzed by a number of different methods, for example, (i) optical density (OD) at 280 nm for protein content, (ii) bovine serum albumin (BSA) protein analysis, (iii) iodine testing for PEG content (Sims *et al.* (1980) *Anal. Biochem.*, 107:60-63), and (iv) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE), followed by staining with barium iodide.

[00195] Separation of positional isomers is typically carried out by reverse phase chromatography using a reverse phase-high performance liquid chromatography (RP-HPLC) C18 column (Amersham Biosciences or Vydac) or by ion exchange chromatography using an ion exchange column, *e.g.*, a DEAE- or CM-Sepharose™ ion exchange column available from Amersham Biosciences. Either approach can be used to separate polymer-OGF peptide isomers having the same molecular weight (positional isomers).

[00196] The resulting purified compositions are preferably substantially free of the non-conjugated OGF peptide. In addition, the compositions preferably are substantially free of all other non-covalently attached water-soluble polymers.

Compositions

Compositions of conjugate isomers

[00197] Also provided herein are compositions comprising one or more of the OGF peptide polymer conjugates described herein. In certain instances, the composition will comprise a plurality of OGF peptide polymer conjugates. For instance, such a composition may comprise a mixture of OGF peptide polymer conjugates having one, two, three and/or even four water-soluble polymer molecules covalently attached to sites on the OGF peptide. That is to say, a composition of the invention may comprise a mixture of monomer, dimer, and possibly even trimer or 4-mer. Alternatively, the composition may possess only mono-conjugates, or only di-conjugates, etc. A mono-conjugate OGF peptide composition will typically comprise OGF peptide moieties having only a single polymer covalently attached thereto, e.g., preferably releasably attached. A mono-conjugate composition may comprise only a single positional isomer, or may comprise a mixture of different positional isomers having polymer covalently attached to different sites within the OGF peptide.

[00198] In yet another embodiment, an OGF peptide conjugate may possess multiple OGF peptides covalently attached to a single multi-armed polymer having 3 or more polymer arms. Typically, the OGF peptide moieties are each attached at the same OGF peptide amino acid site, e.g., the N-terminus.

[00199] With respect to the conjugates in the composition, the composition will typically satisfy one or more of the following characteristics: at least about 85% of the conjugates in the composition will have from one to four polymers attached to the OGF peptide; at least about 85% of the conjugates in the composition will have from one to three polymers attached to the OGF peptide; at least about 85% of the conjugates in the composition will have from one to two polymers attached to the OGF peptide; or at least about 85% of the conjugates in the composition will have one polymer attached to the OGF peptide (e.g., be monoPEGylated); at least about 95% of the conjugates in the composition will have from one to four polymers attached to the OGF peptide; at least about 95% of the conjugates in the composition will have from one to three polymers attached to the OGF peptide; at least about 95% of the conjugates in the composition will have from one to two polymers attached to the OGF peptide; at least about 95% of the conjugates in the composition will have one polymers attached to the OGF peptide; at least about 99% of the conjugates in the composition will have from one to four polymers attached to the OGF peptide; at least about 99% of the conjugates in the composition will have from one to three

polymers attached to the OGF peptide; at least about 99% of the conjugates in the composition will have from one to two polymers attached to the OGF peptide; and at least about 99% of the conjugates in the composition will have one polymer attached to the OGF peptide (*e.g.*, be monoPEGylated).

[00200] In one or more embodiments, the conjugate-containing composition is free or substantially free of albumin.

[00201] In one or more embodiments of the invention, a pharmaceutical composition is provided comprising a conjugate comprising an OGF peptide covalently attached, *e.g.*, releasably, to a water-soluble polymer, wherein the water-soluble polymer has a weight-average molecular weight of greater than about 2,000 Daltons; and a pharmaceutically acceptable excipient.

[00202] Control of the desired number of polymers for covalent attachment to OGF peptide is achieved by selecting the proper polymeric reagent, the ratio of polymeric reagent to the OGF peptide, temperature, pH conditions, and other aspects of the conjugation reaction. In addition, reduction or elimination of the undesired conjugates (*e.g.*, those conjugates having four or more attached polymers) can be achieved through purification means as previously described.

[00203] For example, the water-soluble polymer-(OGF peptide) conjugates can be purified to obtain/isolate different conjugated species. Specifically, the product mixture can be purified to obtain an average of anywhere from one, two, three, or four PEGs per OGF peptide, typically one, two or three PEGs per OGF peptide. In one or more embodiments, the product comprises one PEG per OGF peptide, where PEG is releasably (via hydrolysis) attached to PEG polymer, *e.g.*, a branched or straight chain PEG polymer.

Pharmaceutical Compositions

[00204] Optionally, an OGF peptide conjugate composition of the invention will comprise, in addition to the OGF peptide conjugate, a pharmaceutically acceptable excipient. More specifically, the composition may further comprise excipients, solvents, stabilizers, membrane penetration enhancers, etc., depending upon the particular mode of administration and dosage form.

[00205] Pharmaceutical compositions of the invention encompass all types of formulations and in particular those that are suited for injection, *e.g.*, powders or lyophilates that can be reconstituted as well as liquids, as well as for inhalation. Examples of suitable

diluents for reconstituting solid compositions prior to injection include bacteriostatic endotoxin-free water for injection, dextrose 5% in water, phosphate-buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof. With respect to liquid pharmaceutical compositions, solutions and suspensions are envisioned.

[00206] Exemplary pharmaceutically acceptable excipients include, without limitation, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof.

[00207] Representative carbohydrates for use in the compositions of the present invention include sugars, derivatized sugars such as alditols, aldonic acids, esterified sugars, and sugar polymers. Exemplary carbohydrate excipients suitable for use in the present invention include, for example, monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol), pyranosyl sorbitol, myoinositol and the like. Preferred, in particular for formulations intended for inhalation, are non-reducing sugars, sugars that can form a substantially dry amorphous or glassy phase when combined with the composition of the present invention, and sugars possessing relatively high glass transition temperatures, or Tgs (*e.g.*, Tgs greater than 40°C, or greater than 50°C, or greater than 60°C, or greater than 70°C, or having Tgs of 80°C and above). Such excipients may be considered glass-forming excipients.

[00208] Additional excipients include amino acids, peptides and particularly oligomers comprising 2-9 amino acids, or 2-5 mers, and polypeptides, all of which may be homo or hetero species.

[00209] Exemplary protein excipients include albumins such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, casein, hemoglobin, and the like. The compositions may also include a buffer or a pH-adjusting agent, typically but not necessarily a salt prepared from an organic acid or base. Representative buffers include organic acid salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid. Other suitable buffers include Tris, tromethamine hydrochloride, borate, glycerol phosphate, and phosphate. Amino acids such as glycine are also suitable.

[00210] The compositions of the present invention may also include one or more additional polymeric excipients/additives, *e.g.*, polyvinylpyrrolidones, derivatized celluloses such as hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose,

FICOLLs (a polymeric sugar), hydroxyethylstarch (HES), dextrans (*e.g.*, cyclodextrins, such as 2-hydroxypropyl- β -cyclodextrin and sulfobutylether- β -cyclodextrin), polyethylene glycols, and pectin.

[00211] The compositions may further include flavoring agents, taste-masking agents, inorganic salts (*e.g.*, sodium chloride), antimicrobial agents (*e.g.*, benzalkonium chloride), sweeteners, antioxidants, antistatic agents, surfactants (*e.g.*, polysorbates such as "TWEEN 20" and "TWEEN 80," and pluronics such as F68 and F88, available from BASF), sorbitan esters, lipids (*e.g.*, phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, although preferably not in liposomal form), fatty acids and fatty esters, steroids (*e.g.*, cholesterol), and chelating agents (*e.g.*, zinc and other such suitable cations). The use of certain di-substituted phosphatidylcholines for producing perforated microstructures (*i.e.*, hollow, porous microspheres) may also be employed.

[00212] Other pharmaceutical excipients and/or additives suitable for use in the compositions according to the present invention are listed in "Remington: The Science & Practice of Pharmacy," 21st ed., Williams & Williams, (2005), and in the "Physician's Desk Reference," 60th ed., Medical Economics, Montvale, N.J. (2006).

[00213] The amount of the OGF peptide conjugate (*i.e.*, the conjugate formed between the active agent and the polymeric reagent) in the composition will vary depending on a number of factors, but will optimally be a therapeutically effective amount when the composition is stored in a unit dose container (*e.g.*, a vial). In addition, a pharmaceutical preparation, if in solution form, can be housed in a syringe. A therapeutically effective amount can be determined experimentally by repeated administration of increasing amounts of the conjugate in order to determine which amount produces a clinically desired endpoint.

[00214] The amount of any individual excipient in the composition will vary depending on the activity of the excipient and particular needs of the composition. Typically, the optimal amount of any individual excipient is determined through routine experimentation, *i.e.*, by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects.

[00215] Generally, however, the excipient or excipients will be present in the composition in an amount of about 1% to about 99% by weight, from about 5% to about 98% by weight, from about 15 to about 95% by weight of the excipient, or with concentrations less

than 30% by weight. In general, a high concentration of the OGF peptide is desired in the final pharmaceutical formulation.

Combination of Actives

[00216] A composition of the invention may also comprise a mixture of water-soluble polymer-(OGF peptide) conjugates and unconjugated OGF peptide, to thereby provide a mixture of fast-acting and long-acting OGF peptide.

[00217] Additional pharmaceutical compositions in accordance with the invention include those comprising, in addition to an extended-action OGF peptide water-soluble polymer conjugate as described herein, a rapid acting OGF peptide polymer conjugate where the water-soluble polymer is releasably attached to a suitable location on the OGF peptide.

Administration

[00218] The OGF peptide conjugates of the invention can be administered by any of a number of routes including without limitation, oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal), intrathecal, and pulmonary. Preferred forms of administration include parenteral and pulmonary. Suitable formulation types for parenteral administration include ready-for-injection solutions, dry powders for combination with a solvent prior to use, suspensions ready for injection, dry insoluble compositions for combination with a vehicle prior to use, and emulsions and liquid concentrates for dilution prior to administration, among others.

[00219] In some embodiments of the invention, the compositions comprising the peptide-polymer conjugates may further be incorporated into a suitable delivery vehicle. Such delivery vehicles may provide controlled and/or continuous release of the conjugates and may also serve as a targeting moiety. Non-limiting examples of delivery vehicles include, adjuvants, synthetic adjuvants, microcapsules, microparticles, liposomes, and yeast cell wall particles. Yeast cell walls may be variously processed to selectively remove protein component, glucan, or mannan layers, and are referred to as whole glucan particles (WGP), yeast beta-glucan mannan particles (YGMP), yeast glucan particles (YGP), *Rhodotorula* yeast cell particles (YCP). Yeast cells such as *S.cerevisiae* and *Rhodotorula* sp. are preferred; however, any yeast cell may be used. These yeast cells exhibit different

properties in terms of hydrodynamic volume and also differ in the target organ where they may release their contents. The methods of manufacture and characterization of these particles are described in US Patent Nos. 5,741,495; 4,810,646; 4,992,540; 5,028,703; 5,607,677, and US Patent Applications Nos. 2005/0281781, and 2008/0044438.

[00220] In one or more embodiments of the invention, a method is provided, the method comprising delivering a conjugate to a patient, the method comprising the step of administering to the patient a pharmaceutical composition comprising an OGF peptide polymer conjugate as provided herein. Administration can be effected by any of the routes herein described. The method may be used to treat a patient suffering from a condition that is responsive to treatment with OGF peptide by administering a therapeutically effective amount of the pharmaceutical composition.

[00221] As previously stated, the method of delivering an OGF peptide polymer conjugate as provided herein may be used to treat a patient having a condition that can be remedied or prevented by administration of OGF peptide.

[00222] Certain conjugates of the invention, *e.g.*, releasable conjugates, include those effective to release the OGF peptide, *e.g.*, by hydrolysis, over a period of several hours or even days (*e.g.*, 2-7 days, 2-6 days, 3-6 days, 3-4 days) when evaluated in a suitable *in-vivo* model.

[00223] The actual dose of the OGF peptide conjugate to be administered will vary depending upon the age, weight, and general condition of the subject as well as the severity of the condition being treated, the judgment of the health care professional, and conjugate being administered. Therapeutically effective amounts are known to those skilled in the art and/or are described in the pertinent reference texts and literature. Generally, a conjugate of the invention will be delivered such that plasma levels of an OGF peptide are within a range of about 0.5 picomoles/liter to about 500 picomoles/liter. In certain embodiments the conjugate of the invention will be delivered such that plasma levels of an OGF peptide are within a range of about 1 picomoles/liter to about 400 picomoles/liter, a range of about 2.5 picomoles/liter to about 250 picomoles/liter, a range of about 5 picomoles/liter to about 200 picomoles/liter, or a range of about 10 picomoles/liter to about 100 picomoles/liter.

[00224] On a weight basis, a therapeutically effective dosage amount of an OGF peptide conjugate as described herein will range from about 0.01 mg per day to about 1000 mg per day for an adult. For example, dosages may range from about 0.1 mg per day to about 100 mg per day, or from about 1.0 mg per day to about 10 mg/day. On an activity

basis, corresponding doses based on international units of activity can be calculated by one of ordinary skill in the art.

[00225] The unit dosage of any given conjugate (again, such as provided as part of a pharmaceutical composition) can be administered in a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth. The specific dosing schedule will be known by those of ordinary skill in the art or can be determined experimentally using routine methods. Exemplary dosing schedules include, without limitation, administration five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, once monthly, and any combination thereof. Once the clinical endpoint has been achieved, dosing of the composition is halted.

[00226] It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, the foregoing description as well as the examples that follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

[00227] All articles, books, patents and other publications referenced herein are hereby incorporated by reference in their entireties.

EXPERIMENTAL

[00228] The practice of the invention will employ, unless otherwise indicated, conventional techniques of organic synthesis and the like, which are within the skill of the art. Such techniques are fully explained in the literature. Reagents and materials are commercially available unless specifically stated to the contrary. See, for example, J. March, *Advanced Organic Chemistry: Reactions Mechanisms and Structure*, 4th Ed. (New York: Wiley-Interscience, 1992), *supra*.

[00229] In the following examples, efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.) but some experimental error and deviation should be accounted for. Unless indicated otherwise, temperature is in degrees C and pressure is at or near atmospheric pressure at sea level.

[00230] Although other abbreviations known by one having ordinary skill in the art will be referenced, other reagents and materials will be used, and other methods known by

one having ordinary skill in the art will be used, the following list and methods description is provided for the sake of convenience.

Abbreviations

mPEG-SPA	mPEG-succinimidyl propionate
mPEG-SPC	mPEG-succinimidyl phenyl carbonate
mPEG-SBA	mPEG-succinimidyl butanoate
mPEG-OPSS	mPEG-orthopyridyl-disulfide
mPEG-MAL	mPEG-maleimide, $\text{CH}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-\text{MAL}$
mPEG-SMB	mPEG-succinimidyl α -methylbutanoate, $\text{CH}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}(\text{O})-\text{O}-\text{succinimide}$
mPEG-ButyrALD	$\text{H}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-\text{O}-\text{C}(\text{O})-\text{NH}-(\text{CH}_2\text{CH}_2\text{O})_4-\text{CH}_2\text{CH}_2\text{CH}_2\text{C}(\text{O})\text{H}$
mPEG-PIP	$\text{CH}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-\text{C}(\text{O})-\text{piperidin-4-one}$
mPEG-CM	$\text{CH}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{CH}_2\text{CH}_2-\text{O}-\text{CH}_2-\text{C}(\text{O})-\text{OH}$
anh.	Anhydrous
CV	column volume
Fmoc	9-fluorenylmethoxycarbonyl
NaCNBH_3	sodium cyanoborohydride
HCl	hydrochloric acid
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
NMR	nuclear magnetic resonance
DCC	1,3-dicyclohexylcarbodiimide
DMF	dimethylformamide
DMSO	dimethyl sulfoxide
DI	deionized
MW	molecular weight
K or kDa	kilodaltons
SEC	Size exclusion chromatography
HPLC	high performance liquid chromatography
FPLC	fast protein liquid chromatography
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
MALDI-TOF	Matrix Assisted Laser Desorption Ionization Time-of-Flight

TLC	Thin Layer Chromatography
THF	Tetrahydrofuran

Materials

[00231] All PEG reagents referred to in the appended examples are commercially available unless otherwise indicated.

mPEG reagent preparation

[00232] Typically, a water-soluble polymer reagent is used in the preparation of peptide conjugates of the invention. For purposes of the present invention, a water-soluble polymer reagent is a water-soluble polymer-containing compound having at least one functional group that can react with a functional group on a peptide (*e.g.*, the *N*-terminus, the *C*-terminus, a functional group associated with the side chain of an amino acid located within the peptide) to create a covalent bond. Taking into account the known reactivity of the functional group(s) associated with the water-soluble polymer reagent, it is possible for one of ordinary skill in the art to determine whether a given water-soluble polymer reagent will form a covalent bond with the functional group(s) of a peptide.

[00233] Representative polymeric reagents and methods for conjugating such polymers to an active moiety are known in the art, and are, *e.g.*, described in Harris, J.M. and Zalipsky, S., eds, *Poly(ethylene glycol), Chemistry and Biological Applications*, ACS, Washington, 1997; Veronese, F., and J.M Harris, eds., *Peptide and Protein PEGylation*, *Advanced Drug Delivery Reviews*, 54(4); 453-609 (2002); Zalipsky, S., *et al.*, "Use of Functionalized Poly(Ethylene Glycols) for Modification of Polypeptides" in *Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications*, J. M. Harris, ed., Plenus Press, New York (1992); Zalipsky (1995) *Advanced Drug Reviews* 16:157-182, and in Roberts, *et al.*, *Adv. Drug Delivery Reviews*, 54, 459-476 (2002).

[00234] Additional PEG reagents suitable for use in forming a conjugate of the invention, and methods of conjugation are described in Shearwater Corporation, Catalog 2001; Shearwater Polymers, Inc., Catalogs, 2000 and 1997-1998, and in Pasut, G., *et al.*, *Expert Opin. Ther. Patents* (2004), 14(5). PEG reagents suitable for use in the present invention also include those available from NOF Corporation (Tokyo, Japan), as described generally on the NOF website (2006) under Products, High Purity PEGs and Activated PEGs. Products listed therein and their chemical structures are expressly incorporated herein by reference. Additional PEGs for use in forming a GLP-1 conjugate of the invention include

those available from Polypure (Norway) and from QuantaBioDesign LTD (Powell, Ohio), where the contents of their online catalogs (2006) with respect to available PEG reagents are expressly incorporated herein by reference.


[00235] In addition, water-soluble polymer reagents useful for preparing peptide conjugates of the invention is prepared synthetically. Descriptions of the water-soluble polymer reagent synthesis can be found in, for example, U.S. Patent Nos. 5,252,714, 5,650,234, 5,739,208, 5,932,462, 5,629,384, 5,672,662, 5,990,237, 6,448,369, 6,362,254, 6,495,659, 6,413,507, 6,376,604, 6,348,558, 6,602,498, and 7,026,440.

Example OGF1

OGF-mPEG conjugates

a) mPEG-N^{ter}-OGF via mPEG-SPC

[00236] OGF is prepared and purified according to standard automated peptide synthesis or recombinant techniques known to those skilled in the art. An illustrative polymeric reagent, mPEG-SPC reagent,



'SPC' polymer reagent

is covalently attached to the N-terminus of OGF, to provide a N^{ter}-conjugate form of the peptide. mPEG-SPC 20 kDa, stored at -20 °C under argon, is warmed to ambient temperature. The reaction is performed at room temperature. An X-fold molar excess of mPEG-SPC 20 kDa reagent is used based upon absolute peptide content. The mPEG-SPC reagent is weighed into a glass vial containing a magnetic stirrer bar. A solution of OGF prepared in phosphate buffered saline, PBS, pH 7.4 is added and the mixture is stirred using a magnetic stirrer until the mPEG-SPC is fully dissolved. The stirring speed is reduced and the reaction is allowed to proceed to formation of conjugate product. The reaction is optionally quenched to terminate the reaction. The pH of the conjugate solution at the end of the reaction is measured and further acidified by addition of 0.1M HCl, if necessary, to bring the pH of the final solution to about 5.5. The conjugate solution is then analyzed by SDS-PAGE and RP-HPLC (C18) to determine the extent of mPEG-N^{ter}-OGF conjugate formation.

[00237] Using this same approach, other conjugates are prepared using mPEG derivatives having other weight-average molecular weights that also bear an N-hydroxysuccinimide moiety.


b) OGF- C^{ter} -mPEG

[00238] An illustrative polymeric reagent, mPEG-NH₂ reagent is covalently attached to the C-terminus of OGF, to provide a C^{ter} -conjugate form of the peptide. For coupling to the C-terminus, a protected OGF (Prot-OGF) is prepared and purified according to standard automated peptide synthesis techniques known to those skilled in the art. mPEG-NH₂ 20 kDa, stored at -20 °C under argon, is warmed to ambient temperature. The reaction is performed at room temperature. A X-fold molar excess of mPEG-NH₂, PyBOP (benzotriazol-1-yloxy)tripyrrolidinonophosphonium hexafluorophosphate), and 1-hydroxybenzotriazole (HOBt) are used, based upon absolute peptide content. The mPEG-NH₂, PyBOP, HOBt are weighed into a glass vial containing a magnetic stirrer bar. A solution of Prot-OGF is prepared in *N,N*-dimethylformamide is added and the mixture is stirred using a magnetic stirrer until the mPEG-NH₂ is fully dissolved. The stirring speed is reduced and the reaction is allowed to proceed to formation of conjugate product. The conjugate solution is then analyzed by SDS-PAGE and RP-HPLC (C18) to determine the extent of Prot-OGF- C^{ter} -mPEG conjugate formation. The remaining protecting groups are removed under standard deprotection conditions to yield the OGF- C^{ter} -mPEG conjugate.

[00239] Using this same approach, other conjugates are prepared using mPEG derivatives having other weight-average molecular weights that also bear an amino moiety.

c) OGF-Cys(*S*-mPEG)

[00240] mPEG-Maleimide is obtained having a molecular weight of 5 kDa and having the basic structure shown below:




mPEG-MAL, 5kDa

[00241] OGF, which has a thiol-containing cysteine residue, is dissolved in buffer. To this peptide solution is added a 3-5 fold molar excess of mPEG-MAL, 5 kDa. The mixture is stirred at room temperature under an inert atmosphere for several hours. Analysis of the reaction mixture reveals successful conjugation of this peptide.

[00242] Using this same approach, other conjugates are prepared using mPEG-MAL having other weight average molecular weights.

d) mPEG-N^{ter}-OGF via mPEG-SMB

[00243] An mPEG-N-Hydroxysuccinimide is obtained having a molecular weight of 5 kDa and having the basic structure shown below:



(mPEG-Succinimidyl α -Methylbutanoate Derivative, 5kDa ("mPEG-SMB"))

[00244] mPEG-SMB, 5kDa, stored at -20 °C under argon, is warmed to ambient temperature. A five-fold excess (relative to the amount of the peptide) of the warmed mPEG-SMB is dissolved in buffer to form a 10% reagent solution. The 10% reagent solution is quickly added to the aliquot of a stock OGF solution and mixed well. After the addition of the mPEG-SMB, the pH of the reaction mixture is determined and adjusted to 6.7 to 6.8 using conventional techniques. To allow for coupling of the mPEG-SMB to the peptide via an amide linkage, the reaction solution is stirred for several hours (*e.g.*, 5 hours) at room temperature in the dark or stirred overnight at 3-8 °C in a cold room, thereby resulting in a conjugate solution. The reaction is quenched with a 20-fold molar excess (with respect to the peptide) of Tris buffer.

[00245] Using this same approach, other conjugates are prepared using mPEG derivatives having other weight-average molecular weights that also bear an N-hydroxysuccinimide moiety.

e) OGF-Glu(O-mPEG)


[00246] An illustrative polymeric reagent, mPEG-NH₂ reagent is covalently attached to the Glu residue of OGF, to provide a Glu-conjugate form of the peptide. For coupling to the Glu residue, a protected OGF (Prot2-OGF) is prepared and purified according to standard

automated peptide synthesis techniques known to those skilled in the art. Deprotection of the Glu(OBz) residue (H_2/Pd) yields the free-Glu carboxylate for subsequent coupling. mPEG-NH₂ 20 kDa, stored at -20 °C under argon, is warmed to ambient temperature. The reaction is performed at room temperature. A 5-fold molar excess of mPEG-NH₂, PyBOP (benzotriazol-1-yloxy)tripyrrolidinonophosphonium hexafluorophosphate), and 1-hydroxybenzotriazole (HOBt) are used, based upon absolute peptide content. The mPEG-NH₂, PyBOP, HOBt are weighed into a glass vial containing a magnetic stirrer bar. A solution of Prot3-OGF is prepared in *N,N*-dimethylformamide is added and the mixture is stirred using a magnetic stirrer until the mPEG-NH₂ is fully dissolved. The stirring speed is reduced and the reaction is allowed to proceed to formation of conjugate product. The conjugate solution is then analyzed by SDS-PAGE and RP-HPLC (C18) to determine the extent of Prot3-OGF-(Glu-O-mPEG) conjugate formation. The remaining protecting groups are removed under standard deprotection conditions to yield the OGF-Glu(O-mPEG) conjugate.

[00247] Using this same approach, other conjugates are prepared using mPEG derivatives having other weight-average molecular weights that also bear an amino moiety.

Example OGF2

PEGylation of Opioid Growth Factor (OGF) with [mPEG2-CAC-FMOC-NHS-40K]



[00248] Stock solutions of 2.0 mg/mL OGF and 200 mG/mL mPEG2-CAC-FMOC-NHS-40K were prepared in 2 mM HCl. To initiate a reaction, the two stock solutions and a 0.5 M MES, pH 6.0, stock solution were brought to 25°C and the three stock solutions were mixed (PEG reagent added last) to give final concentrations of 1.25 mg/mL OGF (2.2 mM), 20 mM MES and a 1.25-fold molar excess of OGF over mPEG2-CAC-FMOC-NHS-40K. After 3 hours at 25 °C the reaction was quenched with 100 mM glycine in 100 mM HCl (10 mM final glycine concentration) for 10 minutes. The quenched reaction mixture was diluted with deionized sterile H₂O until the conductivity of the diluted reaction mixture was below 0.5 mS/cm, and the pH was then adjusted to 6.0 with 1 M NaHCO₃/Na₂CO₃, pH 10.0.

[00249] The mono-PEGylated conjugate was purified from the diluted reaction mixture by anion exchange chromatography using a column packed with Q-HP media (GE Healthcare) and reversed phase chromatography using a column packed with CG17S media (Rohm Haas) on an AKTA Explorer 100 system (GE Healthcare). The AKTA Explorer plumbing system and both columns were sanitized with 1 M HCl and 1 M NaOH before use. The diluted reaction mixture was first loaded onto the Q-HP column that had been equilibrated with 15 column volumes of 20 mM MES, pH 6.0. Unreacted OGF but not mono-[mPEG2-CAC-FMOC-40K]-[OGF] and unreacted PEG bound to the Q-HP resin and the conjugate and unreacted PEG were collected in the column void fraction. Glacial acetic acid was added to the void fraction to a final concentration of 5 % (v/v) and the mixture was loaded onto the CG-71S column that had been equilibrated with 5 % acetic acid/95 % H₂O (v/v) (Solvent A) . After sample loading, the column was washed with 10 column volumes Solvent A to remove unreacted PEG. The conjugate was eluted with a linear gradient from 100% A to 20% A/80 % B [Solvent B was 5% acetic acid/95% acetonitrile (v/v)] over 10 column volumes with a linear flow rate of 90 cm/hour.

[00250] Fractions collected during reverse phase chromatography were analyzed using analytical reversed-phase HPLC. The mobile phases were: A, 0.09% TFA in water, and B, 0.04% TFA in acetonitrile. An Agilent Poroshell SB-300 C8 column (2.1 mm X 75 mm) was used with a flow rate of 0.5 ml/min and a column temperature of 60 °C. Detection was carried out at 280 nm. The column was equilibrated in 0% B and conjugate separation was achieved using the gradient timetable shown in Table OGF2.1.

Time (min)	% Mobile phase A	% Mobile phase B
0.00	100.0	0.0
3.00	100.0	0.0
5.00	80.0	20.0
16.00	40.0	60.0
19.00	40.0	60.0
25.00	20.0	80.0
28.00	20.0	80.0


Table OGF2.1. RP-HPLC timetable.

[00251] Fractions containing pure mono-[mPEG2-CAC-FMOC-40K]-[OGF] as determined by analytical RP-HPLC were pooled, lyophilized and stored at -80 °C.

A typical CG71S reversed phase chromatogram is shown in Fig. OGF2.1. RP-HPLC analysis of the purified conjugate is shown in Fig. OGF2.2, and MALDI-TOF analysis of the purified conjugate is shown in Fig. OGF2.3. The purity of the mono-PEG-conjugate was 100% by RP-HPLC analysis. The mass as determined by MALDI-TOF was within the expected range. Fig. OGF2.1. Typical CG71S reversed phase purification profile of mono-[mPEG2-CAC-FMOC-40K]-[OGF]. The mono-PEGylated conjugate and unreacted PEG are indicated. Fig. OGF2.2. Purity analysis of [mono]-[CAC-PEG2-FOMC-40K]-[OGF] by reversed phase HPLC. The purity of the purified conjugate is determined to be 100% at 280 nm. Fig. OGF2.3. MALDI-TOF spectrum of purified mono-[mPEG2-FMOC-CAC-40K]-[OGF]. The peak at 41997.4 Da is within the expected range for the molecular weight of the mono-PEG-conjugate. The very weak signal is due to the absence of a positive charge on the conjugate.

Example OGF3

PEGylation of Opioid Growth Factor (OGF) with [mPEG2-C2-FMOC-NHS-40K]



[00252] Stock solutions of 2.0 mg/mL OGF and 200 mg/mL mPEG2-C2-FMOC-NHS-40K were prepared in 2 mM HCl. To initiate a reaction, the two stock solutions and a 0.5 M MES, pH 6.0, stock solution were brought to 25°C and the three stock solutions were mixed (PEG reagent added last) to give final concentrations of 1.25 mg/mL OGF (2.2 mM), 20 mM MES and a 1.25-fold molar excess of OGF over mPEG2-C2-FMOC-NHS-40K. After 3 hours at 25 °C the reaction was quenched with 100 mM glycine in 100 mM HCl (10 mM final glycine concentration) for 10 minutes. The quenched reaction mixture was diluted with deionized sterile H₂O until the conductivity of the diluted reaction mixture was below 0.5 mS/cm, and the pH was then adjusted to 6.0 with 1 M NaHCO₃/Na₂CO₃, pH 10.0.

[00253] The mono-PEGylated conjugate was purified from the diluted reaction mixture by anion exchange chromatography using a column packed with Q-HP media (GE Healthcare) and reversed phase chromatography using a column packed with CG17S media (Rohm Haas) on an AKTA Explorer 100 system (GE Healthcare). The AKTA Explorer plumbing system and both columns were sanitized with 1 M HCl and 1 M NaOH before use. The diluted reaction mixture was first loaded onto the Q-HP column that had been

equilibrated with 15 column volumes of 20 mM MES, pH 6.0. Unreacted OGF but not mono-[mPEG2-C2-FMOC-40K]-[OGF] and unreacted PEG bound to the Q-HP resin and the conjugate and unreacted PEG were collected in the column void fraction. Glacial acetic acid was added to the void fraction to a final concentration of 5 % (v/v) and the mixture was loaded onto the CG-71S column that had been equilibrated with 10 column volumes of 5 % acetic acid/95 % H₂O (v/v) (Solvent A). After sample loading, the column was washed with 6 column volumes 5 % acetic acid/20 % ethanol/75 % H₂O (v/v/v) to elute unreacted PEG. The conjugate was eluted with a linear gradient from 100% A to 100 % B [Solvent B was 5% acetic acid/95% acetonitrile (v/v)] over 10 column volume with a linear flow rate of 90 cm/hour.

[00254] Fractions collected during reverse phase chromatography were analyzed using analytical reversed-phase HPLC. The mobile phases were: A, 0.09% TFA in water, and B, 0.04% TFA in acetonitrile. An Agilent Poroshell SB-300 C8 column (2.1 mm X 75 mm) was used with a flow rate of 0.5 ml/min and a column temperature of 60 °C. Detection was carried out at 280 nm. The column was equilibrated in 0% B and conjugate separation was achieved using the gradient timetable shown in Table OGF3.1.

Time (min)	% Mobile phase A	% Mobile phase B
0.00	100.0	0.0
3.00	100.0	0.0
5.00	80.0	20.0
16.00	40.0	60.0
19.00	40.0	60.0
25.00	20.0	80.0
28.00	20.0	80.0

Table OGF3.1. RP-HPLC timetable

[00255] Fractions containing pure mono-[mPEG2-C2-FMOC-40K]-[OGF] as determined by analytical RP-HPLC were pooled, lyophilized and stored at -80 °C.

A typical CG71S reversed phase chromatogram is shown in Fig. OGF3.1. RP-HPLC analysis of the purified conjugate is shown in Fig. OGF3.2, and MALDI-TOF analysis of the purified conjugate is shown in Fig. OGF3.3. The purity of the mono-[mPEG2-C2-FMOC-40K]-[OGF] was 97.1 % by RP-HPLC analysis. The mass as determined by MALDI-TOF was within the expected range.


Fig. OGF3.1. Typical CG71S reverse phase purification profile of mono-[mPEG2-C2-FMOC-40K]-[OGF]. The mono-PEGylated conjugate and unreacted PEG are indicated. The resin was overloaded upon sample loading and mono-[mPEG2-C2-FMOC-40K]-[OGF] was found in the void fraction. The void fraction containing the conjugate was reloaded onto the CG71S column and the conjugate was eluted in a second reversed phase chromatography run (data not shown).

Fig. OGF3.2. Purity analysis of mono-[mPEG2-FMOC-C2-40K]-[OGF] by reversed phase HPLC. The purity of the purified conjugate is determined to be 97.1 % at 280 nm. The peak at 8.15 minutes is OGF.

Fig. OGF3.3. MALDI-TOF spectrum of purified mono-[mPEG2-FMOC-C2-40K]-[OGF]. The peak at 41322.1Da is within the expected range for the molecular weight of the mono-PEG-conjugate. The very weak signal is due to the absence of a positive charge on the conjugate.

Example OGF4

PEGylation of Opioid Growth Factor (OGF) with [mPEG-Butyraldehyde-30K]



[00256] Stock solutions of 2.0 mg/mL OGF and 200 mg/mL mPEG-Butyraldehyde-30K were prepared in 2 mM HCl. To initiate a reaction, the two stock solutions and a 1 M HEPES, pH 7.0, stock solution were brought to 25°C and the three stock solutions were mixed (PEG reagent added last) to give final concentrations of 1.25 mg/mL OGF (2.2 mM), 20 mM HEPES and a 1.25-fold molar excess of OGF over mPEG-Butyraldehyde-30K. After 15 minute reaction at 25 °C, a 50-fold molar excess of NaBH₃CN over PEG was added, and the reaction was allowed to continue for an additional 16 hours at 25 °C. After 16 hr 15 min total reaction time, the reaction was quenched with 100 mM glycine in 100 mM HCl (10 mM final glycine concentration) for 10 minutes. The reaction mixture was diluted with deionized sterile H₂O until the conductivity of the diluted reaction mixture was below 0.5 mS/cm, and the pH was then adjusted to 7.0 with 1 M NaHCO₃/Na₂CO₃, pH 10.0.

[00257] The mono-PEGylated conjugate was purified from the diluted reaction mixture by anion exchange chromatography using a column packed with Q-HP media (GE Healthcare) and reversed phase chromatography using a column packed with CG17S media (Rohm Haas) on an AKTA Explorer 100 system (GE Healthcare). The AKTA Explorer plumbing system and both columns were sanitized with 1 M HCl and 1 M NaOH before use.

The diluted reaction mixture was first loaded onto the Q-HP column that had been equilibrated with 15 column volumes of 20 mM HEPES, pH 7.0. Unreacted OGF but not mono-[mPEG-Butyraldehyde-30K]-[OGF] and unreacted PEG bound to the Q-HP resin and the conjugate and unreacted PEG were collected in the column void fraction. Glacial acetic acid was added to the void fraction to a final concentration of 5 % (v/v) and the mixture was loaded onto the CG-71S column that had been equilibrated with 5 % acetic acid/95 % H₂O (v/v) (Solvent A) . After sample loading, the column was washed with 10 column volumes Solvent A to remove unreacted PEG. The conjugate was eluted with a linear gradient from 100% A to 20% A/80 % B [Solvent B was 5% acetic acid/95% acetonitrile (v/v)] over 20 column volumes with a linear flow rate of 90 cm/hour.

[00258] Fractions collected during reverse phase chromatography were analyzed using analytical reversed-phase HPLC. The mobile phases were: A, 0.09% TFA in water, and B, 0.04% TFA in acetonitrile. An Agilent Poroshell SB-300 C8 column (2.1 mm X 75 mm) was used with a flow rate of 0.5 ml/min and a column temperature of 60 °C. Detection was carried out at 280 nm. The column was equilibrated in 0% B and conjugate separation was achieved using the gradient timetable shown in Table OGF4.1.

Time (min)	% Mobile phase A	% Mobile phase B
0.00	100.0	0.0
3.00	100.0	0.0
5.00	80.0	20.0
16.00	40.0	60.0
19.00	40.0	60.0
25.00	20.0	80.0
28.00	20.0	80.0

Table OGF4.1. RP-HPLC timetable

[00259] Fractions containing pure mono-[mPEG-ButALD-30K]-[OGF] as determined by analytical RP-HPLC were pooled, lyophilized and stored at -80 °C.

A typical CG71S reversed phase chromatogram is shown in Fig. OGF4.1. RP-HPLC analysis of the purified conjugate is shown in Fig. OGF4.2. The purity of the mono-[mPEG-ButALD-FMOC-30K]-[OGF] was 95.3 % by RP-HPLC analysis.


Fig. OGF4.1. Typical CG71S reversed phase purification profile of mono-[mPEG-Butyraldehyde-30K]-[OGF]. The mono-PEGylated conjugate is indicated. The resin was

overloaded upon sample loading and mono-[mPEG-Butyraldehyde-30K]-[OGF] was found in the void fraction. The void fraction containing the conjugate was reloaded onto the CG71S column and the conjugate was eluted in a second reversed phase chromatography run (data not shown).

Fig. OGF4.2. Purity analysis of mono-[mPEG-ButyrAldehyde-30K]-[OGF] by reversed phase HPLC. The purity of the purified conjugate is determined to be 95.3 % at 280 nm. The peak with retention time at 1.69 minutes was acetic acid derived from CG71S reversed phase chromatography.

Example OGF5

PEGylation of Opioid Growth Factor (OGF) with [mPEG-Epoxyde-5K]



[00260] Stock solutions of 2.0 mg/mL OGF and 200 mg/mL mPEG-epoxyde-5K were prepared in 2 mM HCl. To initiate a reaction, the two stock solutions and a 0.5 M MES, pH 6.0, stock solution were brought to 25°C and the three stock solutions were mixed (PEG reagent added last) to give final concentrations of 1.25 mg/mL OGF (2.2 mM), 20 mM MES and a 1.25-fold molar excess of OGF over mPEG-epoxyde-5K over OGF. After 15 hours at 25 °C the reaction was quenched with 100 mM glycine in 100 mM HCl (10 mM final glycine concentration) for 10 minutes. The quenched reaction mixture was diluted with deionized sterile H₂O until the conductivity of the diluted reaction mixture was below 0.5 mS/cm, and the pH was then adjusted to 6.0 with 1 M NaHCO₃/Na₂CO₃, pH 10.0.

[00261] The mono-PEGylated conjugate was purified from the diluted reaction mixture by anion exchange chromatography using a column packed with Q-HP media (GE Healthcare) and reversed phase chromatography using a column packed with CG17S media (Rohm Haas) on an AKTA Explorer 100 system (GE Healthcare). The AKTA Explorer plumbing system and both columns were sanitized with 1 M HCl and 1 M NaOH before use. The diluted reaction mixture was first loaded onto the Q-HP column that had been equilibrated with 15 column volumes of 20 mM MES, pH 6.0. Unreacted OGF but not mono-[mPEG2-CAC-FMOC-40K]-[OGF] and unreacted PEG bound to the Q-HP resin and the conjugate and unreacted PEG were collected in the column void fraction. Glacial acetic acid was added to the void fraction to a final concentration of 5 % (v/v) and the mixture was loaded onto the CG-71S column that had been equilibrated with 5 % acetic acid/95 % H₂O

(v/v) (Solvent A) . After sample loading, the column was washed with 10 column volumes Solvent A to remove unreacted PEG. The conjugate was eluted with a linear gradient from 100% A to 20% A/80 % B [Solvent B was 5% acetic acid/95% acetonitrile (v/v)] over 10 column volumes with a linear flow rate of 90 cm/hour.

[00262] Fractions collected during reverse phase chromatography were analyzed using analytical reversed-phase HPLC. The mobile phases were: A, 0.09% TFA in water, and B, 0.04% TFA in acetonitrile. An Agilent Poroshell SB-300 C8 column (2.1 mm X 75 mm) was used with a flow rate of 0.5 ml/min and a column temperature of 60 °C. Detection was carried out at 280 nm. The column was equilibrated in 0% B and conjugate separation was achieved using the gradient timetable shown in Table OGF5.1.

Time (min)	% Mobile phase A	% Mobile phase B
0.00	100.0	0.0
3.00	100.0	0.0
5.00	80.0	20.0
16.00	40.0	60.0
19.00	40.0	60.0
25.00	20.0	80.0
28.00	20.0	80.0

Table OGF5.1. RP-HPLC timetable


[00263] Fractions containing pure mono-[mPEG-epoxide-5K]-[OGF] as determined by analytical RP-HPLC were pooled, lyophilized and stored at -80 °C. A typical GC71S reversed phase chromatogram is shown in Fig. OGF5.1. RP-HPLC analysis of the purified conjugate is shown in Fig. OGF5.2. The purity of the mono-[mPEG-epoxide-5K]-[OGF] was 100 % by RP-HPLC analysis.

Fig. OGF5.1. Typical CG71S reversed phase purification profile of mono-[mPEG-epoxide-5K]-[OGF]. The mono-PEGylated conjugate is indicated.

Fig. OGF5.2. Purity analysis of mono-[mPEG-epoxide-5K]-[OGF] by reversed phase HPLC. The purity of the purified conjugate is determined to be 100 % at 280 nm.

Example OGF6

PEGylation of Opioid Growth Factor (OGF) with [mPEG-Butyraldehyde-10K]



[00264] Stock solutions of 2.0 mg/mL OGF and 200 mg/mL mPEG-Butyraldehyde-10K were prepared in 2 mM HCl. To initiate a reaction, the two stock solutions and a 1 M HEPES, pH 7.0, stock solution were brought to 25°C and the three stock solutions were mixed (PEG reagent added last) to give final concentrations of 1.25 mg/mL OGF (2.2 mM), 20 mM HEPES and a 1.25-fold molar excess of OGF over mPEG-Butyraldehyde-10K. After 15 minute reaction at 25 °C, a 50-fold molar excess of NaBH₃CN over PEG was added, and the reaction was allowed to continue for an additional 6 hours at 25 °C. After 6 hr 15 min total reaction time, the reaction was quenched with 100 mM glycine in 100 mM HCl (10 mM final glycine concentration) for 10 minutes. The reaction mixture was diluted with deionized sterile H₂O until the conductivity of the diluted reaction mixture was below 0.5 mS/cm, and the pH was then adjusted to 7.0 with 1 M NaHCO₃/Na₂CO₃, pH 10.0.

[00265] The mono-PEGylated conjugate was purified from the diluted reaction mixture by anion exchange chromatography using a column packed with Q-HP media (GE Healthcare) and reversed phase chromatography using a column packed with CG17S media (Rohm Haas) on an AKTA Explorer 100 system (GE Healthcare). The AKTA Explorer plumbing system and both columns were sanitized with 1 M HCl and 1 M NaOH before use. The diluted reaction mixture was first loaded onto the Q-HP column that had been equilibrated with 15 column volumes of 20 mM HEPES, pH 7.0. Unreacted OGF but not mono-[mPEG-Butyraldehyde-10K]-[OGF] and unreacted PEG bound to the Q-HP resin and the conjugate and unreacted PEG were collected in the column void fraction. Glacial acetic acid was added to the void fraction to a final concentration of 5 % (v/v) and the mixture was loaded onto the CG-71S column that had been equilibrated with 5 % acetic acid/95 % H₂O (v/v) (Solvent A) . After sample loading, the column was washed with 10 column volumes Solvent A to remove unreacted PEG. The conjugate was eluted with a linear gradient from 100% A to 20% A/80 % B [Solvent B was 5% acetic acid/95% acetonitrile (v/v)] over 20 column volumes with a linear flow rate of 90 cm/hour.

[00266] Fractions collected during reversed phase chromatography were analyzed using analytical reversed-phase HPLC. The mobile phases were: A, 0.09% TFA in water, and B, 0.04% TFA in acetonitrile. An Agilent Poroshell SB-300 C8 column (2.1 mm X 75 mm) was used with a flow rate of 0.5 ml/min and a column temperature of 60 °C. Detection was carried out at 280 nm. The column was equilibrated in 0% B and conjugate separation was achieved using the gradient timetable shown.

Time (min)	% Mobile phase A	% Mobile phase B
------------	------------------	------------------

0.00	100.0	0.0
3.00	100.0	0.0
5.00	80.0	20.0
16.00	40.0	60.0
19.00	40.0	60.0
25.00	20.0	80.0
28.00	20.0	80.0

Table OGF6.1. RP-HPLC timetable

[00267] Fractions containing pure mono-[mPEG-ButALD-10K]-[OGF] as determined by analytical RP-HPLC were pooled, lyophilized and stored at -80 °C. A typical CG71S reversed phase chromatogram is shown in Fig. OGF6.1. RP-HPLC analysis of the purified conjugate is shown in Fig. OGF6.2. The purity of the mono-[mPEG-ButALD-FMOC-10K]-[OGF] was 100 % by RP-HPLC analysis.

Fig. OGF6.1. Typical CG71S reversed phase purification profile of mono-[mPEG-Butyraldehyde-10K]-[OGF]. The mono-PEGylated conjugate is indicated. The resin was overloaded upon sample loading and mono-[mPEG-Butyraldehyde-10K]-[OGF] was found in the void fraction. The void fraction containing the conjugate was reloaded onto the CG71S column and the conjugate was eluted in a second reversed phase chromatography run (data not shown).

Fig. OGF6.2. Purity analysis of mono-[mPEG-Butyraldehyde-10K]-[OGF] by reversed phase HPLC. The purity of the purified conjugate is determined to be 100 % at 280 nm. The peak with retention time at 1.7 minutes was acetic acid derived from CG71S reversed phase chromatography.

Example OGF7

[00268] Radioligand Competition Binding Assay for OGF Series at Mu and Delta Opioid Receptors

[00269] The binding affinities of OGF (control) and PEG-OGF releasable conjugates were evaluated using radioligand binding assays in membranes prepared from CHO-K1 cells expressing recombinant human μ or δ opioid receptors.

[00270] Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration of radioligand and increasing concentrations (0.01 nM to 10 μ M) of test compound in 100 μ L final volume. The

radioligands used were specific for each receptor type, and the assay conditions are described in Table OGF7.2. Following incubations, the membranes were rapidly filtered through GF/B filter plate (presoaked with 0.5% polyethyleneimine), washed four times with cold 50 mM Tris-HCl, pH 7.5, and the bound radioactivity was then measured. Non-specific binding was measured in the presence of excess naloxone (100 μ M); this value was subtracted from the total binding to yield the specific binding at each test concentration.

[00271] For the releasable PEG-OGF conjugates, the receptor-binding activity of both released OGF and PEG-OGF (unreleased) conjugates was tested. The test compounds were stored under acidic condition to stabilize the PEG conjugation. To test the activity of PEG-OGF conjugates, the sample was diluted on the day of the assay. To test the activity of released OGF, two samples were prepared prior to the assay based on pre-determined release rates (refer to Table OGF7.3); one sample was diluted 10-fold in assay buffer (pre-incubated under physiological-like conditions for a period until ~50% of OGF was estimated to be released) and the other sample was diluted 5-fold in 800 mM lysine solution, pH 10.0 (pre-incubated under forced release conditions for less than 24 hours until ~95% of OGF was estimated to be released).

[00272] IC_{50} (concentration of test compound required to inhibit 50% of specific binding) values were obtained from non-linear regression analysis of dose-response curves, using GraphPad's Prism 5.01 software, and were calculated for those compounds that showed >50% inhibition of specific binding at the highest concentration tested. K_i (affinity of test compound) was obtained using the Cheng Prusoff correction using experimental K_d (affinity of radioligand) values that were previously determined under these assay conditions.

[00273] The binding affinities of OGF and PEG-OGF conjugates are shown in Table OGF7.1. Opioid growth factor displayed similar, high affinity (1.3-2.0 nM) for human μ and δ opioid receptors.

[00274] Since the releasable conjugates were pre-incubated, OGF was also pre-incubated for the maximum period to test the activity of the peptide itself under the pre-incubation treatment conditions. As shown in Figure OGF7.1, OGF remained stable following pre-incubation under physiological-like (160 hours at 37°C, pH 7.5) and forced release conditions (16 hours at 37°C, pH 10.0). Pre-incubated OGF displayed similar, high affinity for μ and δ opioid receptors when compared to the control prepared on the day of the assay (Table OGF7.1).

[00275] Following pre-incubation of mono-mPEG2-CAC-40K-OGF for 160 hours and mono-mPEG2-C2-40K-OGF for 68 hours under physiological-like conditions, affinity for μ

and δ opioid receptors was increased (compared to PEG-OGF conjugates prepared on the day of the assay) and regained (Figure OGF7.2); OGF released from these conjugates retained receptor binding activity as shown by <9-fold loss in affinity relative to OGF. Similarly, both PEG-OGF conjugates treated under forced release conditions displayed release of active OGF and high affinity binding to μ and δ opioid receptors as shown by <4-fold loss in affinity relative to OGF.

[00276] The mono-mPEG2-CAC-40K-OGF conjugate displayed much lower affinity for both receptors; reduction in affinity was 135 to 150-folds less relative to OGF. The mono-mPEG2-C2-40K-OGF conjugate displayed a 2-fold reduction in affinity at the μ opioid and δ opioid receptor; this slight loss in affinity suggests that the mono-mPEG2-C2-40K linker may have been unstable and resulted in faster release of OGF under the assay conditions.

[00277] For the free PEGs (CAC-40K-fulvene and C2-40K-fulvene), affinity for μ and δ opioid receptors was not seen as expected. As shown in Figure OGF7.3, binding affinity could not be determined for the free PEGs since >50% inhibition of specific binding was not achieved up to the highest test concentration (10 μ M).

Figure OGF7.1. Competition binding assay of OGF at human (A) μ opioid and (B) δ opioid receptors: effects of incubation treatment conditions. Data presented as mean (\pm SEM) percent specific binding.

Figure OGF7.2. Competition binding assay of OGF and PEG-OGF conjugates (released and unreleased) at human (A) μ opioid and (B) δ opioid receptors. Data presented as mean (\pm SEM) percent specific binding.

Figure OGF7.3. Competition binding assay of OGF and free PEGs at human (A) μ opioid and (B) δ opioid receptors. Data presented as mean (\pm SEM) percent specific binding.

Table OGF7.1. Summary of binding affinities for OGF, PEG-OGF conjugates, and free PEG.

Compound	μ Opioid Receptor		δ Opioid Receptor	
	Ki (nM)	Fold Change Relative to OGF	Ki (nM)	Fold Change Relative to OGF
OGF	1.5	1.0	1.8	1.0
OGF (Pre-incubated)	1.3	0.8	1.7	1.0
Mono-mPEG2-FMOC-CAC-40K-OGF (Pre-incubated)	10.8	7.2	15.2	8.6

Mono-mPEG2-FMOC-C2-40K-OGF (Pre-incubated)	4.3	2.9	3.5	2.0
CAC-40K-fulvene (Free PEG)	Not obtained	Not obtained	Not obtained	Not obtained
C2-40K-fulvene (Free PEG)	Not obtained	Not obtained	Not obtained	Not obtained
OGF (Forced release)	1.3	0.9	2.0	1.1
Mono-mPEG2-FMOC-CAC-40K-OGF (Forced release)	5.8	3.9	6.5	3.7
Mono-mPEG2-FMOC-C2-40K-OGF (Forced release)	3.3	2.2	3.2	1.8
Mono-mPEG2-FMOC-CAC-40K-OGF	223.9	149.9	237.3	134.6
Mono-mPEG2-FMOC-C2-40K-OGF	3.2	2.2	2.6	1.5

Not obtained = K_i values could not be determined since >50% inhibition of specific binding was not achieved at the highest concentration tested.

Table OGF7.2. Assay conditions.

Receptor	Receptor Source	Membrane Protein	Radioligand	K_d	Non-specific binding	Methods
μ Opioid	Human recombinant CHO-K1 cells	5 μ g/well	[3 H] Naloxone (5 nM)	2.0 nM	Naloxone (100 μ M)	Reaction in 50 mM Tris-HCl (pH 7.5) at 25°C for 1 h on plate shaker
δ Opioid	Human recombinant CHO-K1 cells	15 μ g/well	[3 H] DPDPE (5 nM)	3.0 nM	Naloxone (100 μ M)	Reaction in 50 mM Tris-HCl (pH 7.5), 5 mM MgCl ₂ , 0.1% BSA at 25°C for 1 h on plate shaker

Table OGF7.3. Compounds.

Compound	MW (Da)	Stock conc. based on peptide (mg/mL)	Storage buffer	OGF Release rate	Pre-incubation condition	Forced release condition
OGF	574	2.0	100 mM HEPES	-	160 h in 50 mM Tris-HCl, 5 mM MgCl ₂ , 0.1% BSA, pH 7.5 at 37°C	16 h in 800 mM lysine, pH 10.0 at 37°C
Mono-mPEG2-FMOC-CAC-40K-OGF; releasable PEG	41,332	4.4	2 mM HCl	7.7 % after 68 h at 37°C in 150 mM Pi + 150 mM NaCl, pH 7.4. 95 % within 24 h in 200 mM lysine, pH 10.0	160 h in 50 mM Tris-HCl, 5 mM MgCl ₂ , 0.1% BSA, pH 7.5 at 37°C	16 h in 800 mM lysine, pH 10.0 at 37°C
Mono-mPEG2-FMOC-C2-40K-OGF; Releasable	41,332	5.0	2 mM HCl	46 % after 48 h at 37°C in 150 mM Pi + 150 mM NaCl, pH 7.4.	68 h in 50 mM Tris-HCl, 5 mM MgCl ₂ , 0.1% BSA, pH 7.5 at 37°C	16 h in 800 mM lysine, pH 10.0 at 37°C

Compound	MW (Da)	Stock conc. based on peptide (mg/mL)	Storage buffer	OGF Release rate	Pre- incubation condition	Forced release condition
				97.8% within 24 h in 200 mM lysine, pH 10.0		

Figure OGF7.1. Competition binding assay of OGF at human (A) μ opioid and (B) δ opioid receptors: effects of incubation treatment conditions.

Figure OGF7.2. Competition binding assay of OGF and PEG-OGF conjugates (released and unreleased) at human (A) μ opioid and (B) δ opioid receptors.


Figure 3. Competition binding assay of OGF and free PEGs at human (A) μ opioid and (B) δ opioid receptors.

What is claimed is:

1. A conjugate comprising a residue of a OGF moiety covalently attached, either directly or through a spacer moiety of one or more atoms, to a water-soluble, non-peptidic polymer.
2. A conjugate of claim 1, wherein the polymer is a linear polymer.
3. A conjugate of claim 1, wherein the polymer is a branched polymer.
4. The conjugate of any one of claims 1, 2 and 3, wherein the OGF moiety is recombinantly prepared.
5. The conjugate of any one of claims 1, 2 and 3, wherein the OGF moiety is prepared by chemical synthesis.
6. The conjugate of any one of claims 1 to 5, wherein the polymer is selected from the group consisting of poly(alkylene oxide), poly(vinyl pyrrolidone), poly(vinyl alcohol), polyoxazoline, and poly(acryloylmorpholine).
7. The conjugate of claim 6, wherein the polymer is a poly(alkylene oxide).
8. The conjugate of claim 7, wherein the poly(alkylene oxide) is a poly(ethylene glycol).
9. The conjugate of claim 8, wherein the poly(ethylene glycol) is terminally capped with an end-capping moiety selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, alkynoxy, substituted alkynoxy, aryloxy and substituted aryloxy.
10. The conjugate of claim 8, wherein the the poly(ethylene glycol) has a weight-average molecular weight in a range of from about 500 Daltons to about 100,000 Daltons.
11. The conjugate of claim 10, wherein the the poly(ethylene glycol) has a weight-average molecular weight in a range of from about 2000 Daltons to about 50,000 Daltons.


12. The conjugate of claim 11, wherein the the poly(ethylene glycol) has a weight-average molecular weight in a range of from about 5000 Daltons to about 40,000 Daltons.
13. The conjugate of any of the preceding claims, wherein the water-soluble, non-peptidic polymer is conjugated at an amino-terminal amino acid of the OGF moiety.
14. The conjugate of any of the preceding claims, wherein the water-soluble, non-peptidic polymer is conjugated at a carboxy-terminal amino acid of the OGF moiety.
15. The conjugate of any of the preceding claims, wherein the water-soluble, non-peptidic polymer is conjugated at an internal cysteine amino acid of the OGF moiety.
16. The conjugate of any of the preceding claims, wherein the water-soluble, non-peptidic polymer is conjugated at an epsilon amino group of an internal lysine amino acid of the OGF moiety.

17. The conjugate of claim 8, wherein the polymeric reagent has the following structure:




wherein, (n) is independently an integer having a value of from about 2 to about 4000.

18. The conjugate of claim 8, wherein the polymeric reagent has the following structure:



Wherein, (n) is independently an integer having a value of from about 2 to about 4000.

19. The conjugate of claim 8, wherein the polymeric reagent has the following structure:



wherein, (n) is independently an integer having a value of from about 2 to about 4000.

20. The conjugate of any one of the preceding claims, wherein the OGF residue is covalently attached through a spacer moiety of one or more atoms.
21. The conjugate of claim 20, wherein the spacer moiety includes an amine linkage.
22. The conjugate of claim 20, wherein the spacer moiety includes an amide linkage.
23. The conjugate of claim 20, wherein the spacer moiety includes a disulfide linkage.
24. The compound of any one of the preceding claims, wherein the OGF residue is covalently attached via a stable linkage.
25. The compound of any one of the preceding claims, wherein the OGF residue is covalently attached via a releasable linkage.
26. A pharmaceutical composition comprising a conjugate of any one of the preceding claims and a pharmaceutically acceptable excipient.
27. A method for making a conjugate comprising contacting, under conjugation conditions, a OGF moiety with a polymeric reagent bearing a functional group.
28. A method of treatment comprising administering a compound of any of the preceding claims to a subject in need thereof.

1/15




Figure OGF2.1

MWD1 B, Sig=280,16 Ref=360,100 (XLOGF CON...JUGATE PURITY 0712809 2009-07-28 16-38-30\INS-DEX-PEGPH71.D)





Figure OGF2.2

3/15



Acquisition Parameter

Date of acquisition	2009-08-04T12:52:30.515-07:00
Acquisition method name	D:\Methods\flexControlMethods\LP_44kDa.par
Spectrum type	TOF
Parent ion mass for ms/ms spectra	
Precursor ion selector lower mass limit	
Precursor ion selector upper mass limit	
C/D valve/mode	
Number of shots	100

Figure OGF2.3

4/15




Figure OGF3.1

5/15

MWD1 B, Sig=280,16 Ref=360,100 (XL OGF CON...JUGATE PURITY 0712809 2009-07-28 17-32-49\INS-DEX-PEGPH74.D)





Figure OGF3.2

6/15



Acquisition Parameter

Date of acquisition	2009-08-04T12:58:37.687-07:00
Acquisition method name	D:\Methods\flexControlMethods\LP_44kDa.par
Spectrum type	TOF
Parent ion mass for ms/ms spectra	
Precursor ion selector lower mass limit	
Precursor ion selector upper mass limit	
C/D valve/mode	
Number of shots	100

Figure OGF3.3

7/15

XL CG71S 34 mL OGF C2 LSC Run1001:10_UV1_280nm
XL CG71S 34 mL OGF C2 LSC Run1001:10_Conc
XL CG71S 34 mL OGF C2 LSC Run1001:10_Logbook

XL CG71S 34 mL OGF C2 LSC Run1001:10_UV2_320nm
XL CG71S 34 mL OGF C2 LSC Run1001:10_Fractions




Figure OGF4.1

8/15




Figure OGF4.2

9/15




Figure OGF5.1

10/15




Figure OGF5.2

11/15




Figure OGF6.1

12/15

DAD1 B, Sig=280,16 Ref=360,100 (XLOGFBUTALD10K 021809 CG71S FRN1BE-0501.D)




Figure OGF6.2

13/15

μ Opioid Receptor (Human Recombinant) Binding Assay




Figure OGF7.1A

δ Opioid Receptor (Human Recombinant) Binding Assay




Figure OGF7.1B

14/15

μ Opioid Receptor (Human Recombinant) Binding Assay




Figure OGF7.2A

δ Opioid Receptor (Human Recombinant) Binding Assay




Figure OGF7.2B

15/15




Figure OGF7.3A




Figure OGF7.3B

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/005212

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K47/48 C07K7/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WITT K A ET AL: "PHARMACODYNAMIC AND PHARMACOKINETIC CHARACTERIZATION OF POLY(ETHYLENE GLYCOL) CONJUGATION TO MET-ENKEPHALIN ANALOG not D-PEN2,D-PEN5 3/4 ENKEPHALIN (DPDPE)" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 298, no. 2, 1 August 2001 (2001-08-01), pages 848-856, XP001020459 ISSN: 0022-3565 whole document, in particular compound PEG-DPDPE</p> <p align="center">----- -/--</p>	1-28

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 3 February 2010	Date of mailing of the international search report 11/02/2010
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Schleifenbaum, A
--	---

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/005212

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/24831 A2 (SHEARWATER POLYMERS INC [US]; BENTLEY MICHAEL DAVID [US]; ROBERTS MICH) 12 April 2001 (2001-04-12) page 14, line 8 - line 12; claims 1-3,6-16,; example 5 -----	1-28
X	WO 00/09073 A2 (PROTEIN DELIVERY INC [US]; EKWURIBE NNOCHIRI N [US]; RADHAKRISHNAN BAL) 24 February 2000 (2000-02-24) whole application, in particular compounds page 9, line 17 - page 11, line 10 -----	1-9, 14-16, 20-28
X	MAEDA M ET AL: "Amino acids and peptides. XXIV. Preparation and antinociceptive effect of [D-Ala ² ,(N-Me)Phe ⁴]enkephalin analog-poly(ethylene glycol) hybrids." CHEMICAL & PHARMACEUTICAL BULLETIN SEP 1994, vol. 42, no. 9, September 1994 (1994-09), pages 1859-1863, XP8118255 ISSN: 0009-2363 PEG compounds in Table 1. -----	1-28
X	SASAKI-YAGI Y ET AL: "BINDING OF ENKEPHALIN/DEXTRAN CONJUGATES TO OPIOID RECEPTORS" INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, MUNKSGAARD, COPENHAGEN, DK, vol. 43, no. 3, 1 March 1994 (1994-03-01), pages 219-224, XP000433028 ISSN: 0367-8377 Compounds in Table 1 -----	1-2,5, 13,16, 20-21, 24,26-28
X	COLOMBO R ET AL: "Synthesis of leucine-enkephalin and methionine-enkephalin on a p-alkoxybenzyl-modified soluble support" HOPPE-SEYLER'S ZEITSCHRIFT FUER PHYSIOLOGISCHE CHEMIE, WALTER DE GRUYTER, BERLIN, DE, vol. 362, 1 October 1981 (1981-10-01), pages 1385-1391, XP008093373 ISSN: 0018-4888 Figure, Intermediates (C)->I and (D)->II, "Materials and Methods" -----	1-2, 5-12,14, 20,22, 24-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2009/005212

Patent document cited in search report	Publication date	Publication date	Patent family member(s)	Publication date
WO 0124831	A2	12-04-2001	AT 347377 T	15-12-2006
			AU 782298 B2	14-07-2005
			AU 1631201 A	10-05-2001
			CA 2385533 A1	12-04-2001
			DE 60032255 T2	28-06-2007
			EP 1221975 A2	17-07-2002
			ES 2275561 T3	16-06-2007
			JP 4027663 B2	26-12-2007
			JP 2003511357 T	25-03-2003
			MX PA02003176 A	30-09-2002
WO 0009073	A2	24-02-2000	AU 772494 B2	29-04-2004
			AU 5672699 A	06-03-2000
			BR 9914280 A	13-11-2001
			CA 2340418 A1	24-02-2000
			CN 1323213 A	21-11-2001
			EP 1105142 A2	13-06-2001
			JP 2002522463 T	23-07-2002
			MX PA01001694 A	08-04-2002
			US 6703381 B1	09-03-2004
			US 6956051 B1	18-10-2005
			US 6943148 B1	13-09-2005
			US 2004102381 A1	27-05-2004
			US 2004110735 A1	10-06-2004